




FORM PTO-1390 (Modified) (REV 10-95)		U.S. GOVERNMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				10441
INTERNATIONAL APPLICATION NO <b>PCT/AU96/00094</b>		INTERNATIONAL FILING DATE <b>22 February 1996 (22.03.96)</b>		U.S. APPLICATION NO (IF KNOWN, SEE 37 CFR <b>08/765588</b>
TITLE OF INVENTION <b>A NOVEL GROWTH FACTOR AND A GENETIC SEQUENCE ENCODING SAME</b>		PRIORITY DATE CLAIMED <b>(02.03.95), (20.11.95), and (22.12.95)</b>		
APPLICANT(S) FOR DO/EO/US <b>Nicholas Kim Hayward, Gunther Weber, Sean Grimmond, Magnus Nordenskjold, and Catharina Larsson</b>				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </li> <li>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ul> </li> <li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> </ol>				
<p><b>Items 11 to 16 below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment. A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>14. <input type="checkbox"/> A substitute specification.</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input checked="" type="checkbox"/> Other items or information:</li> </ol>				
<b>Courtesy Copy of international application</b>				

U.S. APPLICATION NO (IF KNOWN, SEE 37 CFR	INTERNATIONAL APPLICATION NO. PCT/AU96/00094	ATTORNEY'S DOCKET NUMBER 10441												
<p>17. The following fees are submitted:</p> <p><b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</b></p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%;">Search Report has been prepared by the EPO or JPO .....</td> <td style="width: 30%; text-align: right;">\$910.00</td> </tr> <tr> <td>International preliminary examination fee paid to USPTO (37 CFR 1.482) .....</td> <td style="text-align: right;">\$700.00</td> </tr> <tr> <td>No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....</td> <td style="text-align: right;">\$770.00</td> </tr> <tr> <td>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....</td> <td style="text-align: right;">\$1,040.00</td> </tr> <tr> <td>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....</td> <td style="text-align: right;">\$96.00</td> </tr> </table>		Search Report has been prepared by the EPO or JPO .....	\$910.00	International preliminary examination fee paid to USPTO (37 CFR 1.482) .....	\$700.00	No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....	\$770.00	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	\$1,040.00	International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....	\$96.00	<b>CALCULATIONS PTO USE ONLY</b>		
Search Report has been prepared by the EPO or JPO .....	\$910.00													
International preliminary examination fee paid to USPTO (37 CFR 1.482) .....	\$700.00													
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....	\$770.00													
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	\$1,040.00													
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....	\$96.00													
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		<b>\$1,040.00</b>												
<p>Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%;">□ 20</td> <td style="width: 30%; text-align: right;">□ 30</td> </tr> </table>		□ 20	□ 30	<b>\$0.00</b>										
□ 20	□ 30													
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>52 - 20 =</td> <td>32</td> <td>x \$22.00</td> </tr> <tr> <td>Independent claims</td> <td>10 - 3 =</td> <td>7</td> <td>x \$80.00</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	52 - 20 =	32	x \$22.00	Independent claims	10 - 3 =	7	x \$80.00	<b>\$704.00</b>
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE											
Total claims	52 - 20 =	32	x \$22.00											
Independent claims	10 - 3 =	7	x \$80.00											
<p>Multiple Dependent Claims (check if applicable).</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; text-align: right;">□</td> <td style="width: 30%; text-align: right;">\$0.00</td> </tr> </table>		□	\$0.00	<b>\$0.00</b>										
□	\$0.00													
<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$2,304.00</b>												
<p>Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; text-align: right;">□</td> <td style="width: 30%; text-align: right;">\$0.00</td> </tr> </table>		□	\$0.00	<b>\$0.00</b>										
□	\$0.00													
<b>SUBTOTAL =</b>		<b>\$2,304.00</b>												
<p>Processing fee of <b>\$130.00</b> for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%;">□ 20</td> <td style="width: 30%; text-align: right;">□ 30</td> </tr> </table>		□ 20	□ 30	<b>\$0.00</b>										
□ 20	□ 30													
<b>TOTAL NATIONAL FEE =</b>		<b>\$2,304.00</b>												
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; text-align: right;">□</td> <td style="width: 30%; text-align: right;">\$0.00</td> </tr> </table>		□	\$0.00	<b>\$0.00</b>										
□	\$0.00													
<b>TOTAL FEES ENCLOSED =</b>		<b>\$2,304.00</b>												
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; text-align: right;">Amount to be: refunded</td> <td style="width: 30%; text-align: right;">\$</td> </tr> <tr> <td style="text-align: right;">charged</td> <td style="text-align: right;">\$</td> </tr> </table>		Amount to be: refunded	\$	charged	\$	<b>\$</b>								
Amount to be: refunded	\$													
charged	\$													
<p><input checked="" type="checkbox"/> A check in the amount of <b>\$2,304.00</b> to cover the above fees is enclosed.</p> <p><input type="checkbox"/> Please charge my Deposit Account No. in the amount of to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p><input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. <b>19-1013</b> A duplicate copy of this sheet is enclosed.</p>														
<p><b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b></p> <p>SEND ALL CORRESPONDENCE TO:</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; padding: 5px;"> <b>Leopold Presser</b>            Registration No.: 19,827         </td> <td style="width: 30%; padding: 5px; text-align: right;"> <b>SIGNATURE</b>    <b>Leopold Presser</b>  <b>NAME</b>  <b>19,827</b>  <b>REGISTRATION NUMBER</b>  <b>December 17, 1996</b>  <b>DATE</b> </td> </tr> </table> <p><b>Scully, Scott, Murphy &amp; Presser</b>  <b>400 Garden City Plaza</b>  <b>Garden City, NY 11530</b>  <b>(516)742-4343</b></p>			<b>Leopold Presser</b> Registration No.: 19,827	<b>SIGNATURE</b>  <b>Leopold Presser</b> <b>NAME</b> <b>19,827</b> <b>REGISTRATION NUMBER</b> <b>December 17, 1996</b> <b>DATE</b>										
<b>Leopold Presser</b> Registration No.: 19,827	<b>SIGNATURE</b>  <b>Leopold Presser</b> <b>NAME</b> <b>19,827</b> <b>REGISTRATION NUMBER</b> <b>December 17, 1996</b> <b>DATE</b>													

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): Nicholas Kim Hayward, et al.

Docket No.

10441

Serial No.  
unassignedFiling Date  
HerewithExaminer  
N/AGroup Art Unit  
N/AInvention. **A NOVEL GROWTH FACTOR AND A GENETIC SEQUENCE ENCODING SAME**I hereby certify that this New PCT Application*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on  
December 17, 1996

*(Date)*Karen DeSalvo*(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)*EM357905877US*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**

A NOVEL GROWTH FACTOR AND A GENETIC SEQUENCE  
ENCODING SAME

5 The present invention relates generally to an isolated molecule having vascular endothelial growth factor-like properties and to a genetic sequence encoding same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of conditions requiring enhanced or diminished vasculature and/or vascular permeability. The molecule of the present  
10 invention is also a useful effector of primary and central neurons and is capable of inducing astroglial proliferation.

Bibliographic details of the publications referred to by author in this specification are collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for  
15 the nucleotide and amino acid sequences referred to in the specification are defined following the bibliography.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to  
20 imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Vascular endothelial growth factor (hereinafter referred to as "VEGF"), also known as vasoactive permeability factor, is a secreted, covalently linked homodimeric glycoprotein  
25 that specifically activates endothelial tissues (Senger *et al.*, 1993). A range of functions have been attributed to VEGF such as its involvement in normal angiogenesis including formation of the corpus luteum (Yan *et al.*, 1993) and placental development (Sharkey *et al.*, 1993), regulation of vascular permeability (Senger *et al.*, 1993), inflammatory angiogenesis (Sunderkotter *et al.*, 1994) and autotransplantation (Dissen *et al.*, 1994) and  
30 human diseases such as tumour promoting angiogenesis (Folkman & Shing, 1992), rheumatoid arthritis (Koch *et al.*, 1994) and diabetes related retinopathy (Folkman & Shing, 1992).

VEGF is, therefore, an important molecule making it a potentially valuable target for research into therapeutics, prophylactics and diagnostic agents based on VEGF or its activities. There is also a need to identify homologues or otherwise related molecules for use as an alternative to VEGF or in conjunction with VEGF.

5

In work leading up to the present invention, the inventors sought the multiple endocrine neoplasia type I susceptibility gene (MEN1). Surprisingly, the inventors discovered that a genetic sequence excluded as a candidate for the MEN1 gene was nevertheless a new growth factor having some similarity to VEGF. Furthermore, the growth factor of the 10 present invention is an effector molecule for primary and central neurons.

Accordingly, one aspect of the present invention comprises a biologically isolated proteinaceous molecule comprising a sequence of amino acids which:

- (i) is at least about 15% similar to the amino acid sequence set forth in SEQ ID 15 NO:2; and
- (ii) is at least 5% dissimilar to the amino acid sequence set forth in SEQ ID NO:2.

Another aspect of the present invention provides a biologically isolated proteinaceous molecule having the following characteristics:

- 20 (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to all or part of the amino acid sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one property in common with VEGF.

- 25 A related aspect of the present invention contemplates a biologically isolated proteinaceous molecule having the following characteristics:

- (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to the amino acid sequence set forth in SEQ ID NO:2;
- 30 (ii) exhibits at least one of the following properties:
  - (a) ability to induce proliferation of vascular endothelial cells;
  - (b) ability to interact with *flt-1/flk-1* family of receptors;

- 3 -

(c) ability to induce cell migration, cell survival and/or an increase in intracellular levels of alkaline phosphatase.

By "biologically isolated" is meant that the molecule has undergone at least one step of 5 purification from a biological source. Preferably, the molecule is also biologically pure meaning that a composition comprises at least about 20%, more preferably at least about 40%, still more preferably at least about 65%, even still more preferably at least about 80-90% or greater of the molecule as determined by weight, activity or other convenient means, relative to other compounds in the composition. Most preferably, the molecule 10 is sequencably pure.

Another preferred aspect of the present invention provides the molecule in recombinant form.

15 According to this aspect of the present invention, there is provided a recombinant molecule comprising a sequence of amino acids which:

- (i) is at least about 15% similar to the amino acid sequence set forth in SEQ ID NO:2; and
- (ii) is at least 5% dissimilar to the amino acid sequence set forth in SEQ ID NO:2.

20

A related aspect of the present invention is directed to a recombinant molecule having the following characteristics:

25 (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to all or part of the amino acid sequence set forth in SEQ ID NO:2;

- (ii) exhibits at least one property in common with VEGF.

A further related aspect of the present invention contemplates a recombinant molecule having the following characteristics:

30 (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to the amino acid sequence set forth in SEQ ID NO:2;

5 (ii) exhibits at least one of the following properties:

- (a) ability to induce proliferation of vascular endothelial cells;
- (b) ability to interact with *flt-1/flk-1* family of receptors;
- (c) ability to induce cell migration, cell survival and/or an increase in intracellular levels of alkaline phosphatase.

The present invention also contemplates genomic or partial genome clones encoding a proteinaceous molecule having at least about 15% amino acid similarity but at least about 5% dissimilarity to SEQ ID NO:1.

10

The amino acid sequence set forth in SEQ ID NO:2 corresponds to human VEGF (referred to herein as "VEGF<sub>165</sub>"). Accordingly, the molecule of the present invention is VEGF-like or is a homologue of VEGF but comprises an amino acid sequence which is similar but non-identical to the amino sequence of VEGF. Although the present invention is exemplified using a human VEGF-like molecule, this is done with the understanding that the instant invention contemplates the homologous molecule and encoding sequence from other mammals such as livestock animals (e.g. sheep, pigs, horses and cows), companion animals (e.g. dogs and cats) and laboratory test animals (e.g. mice, rats, rabbits and guinea pigs) as well as non-mammals such as birds (e.g. 15 poultry birds), fish and reptiles. In a most preferred embodiment, the VEGF-like molecule is of human origin and encoded by a gene located at chromosome 11q13. The present invention extends, therefore, to the genomic sequence or part thereof encoding the subject VEGF-like molecule.

20

25 Preferably, the percentage similarity is at least about 30%, more preferably at least about 40%, still more preferably at least about 50%, still even more preferably at least about 60-70%, yet even more preferably at least about 80-95% to all or part of the amino acid sequence set forth in SEQ ID NO:2.

30 In a particularly preferred embodiment, the VEGF-like molecule of the present invention comprises a sequence of amino acids as set forth in SEQ ID NO:4 or is a part, fragment, derivative or analogue thereof. Particularly preferred similarities include about 19-20%,

and 29-30%. Reference herein to derivatives also includes splice variants. Accordingly, the present invention extends to splice variants of SOM175. Examples of splice variants contemplated by the present invention include but are not limited to variants with an amino acid sequence substantially as set forth in at least one of SEQ ID NO:6, SEQ ID 5 NO:8 and/or SEQ ID NO:10 or mutants or derivatives or further splice variants thereof.

Another embodiment provides a recombinant molecule having the following characteristics:

- (i) an amino acid sequence substantially as set forth in SEQ ID NO:4 or having at least about 15% similarity to all or part thereof provided that said amino acid sequence is at least about 5% dissimilar to all or part of the amino acid sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one biological property in common with VEGF.

15 Another embodiment provides a recombinant molecule having the following characteristics:

- (i) an amino acid sequence substantially as set forth in SEQ ID NO:6 or having at least about 15% similarity to all or part thereof provided that said amino acid sequence is at least about 5% dissimilar to all or part of the amino acid sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one biological property in common with VEGF.

Another embodiment provides a recombinant molecule having the following characteristics:

25 (i) an amino acid sequence substantially as set forth in SEQ ID NO:8 or having at least about 15% similarity to all or part thereof provided that said amino acid sequence is at least about 5% dissimilar to all or part of the amino acid sequence set forth in SEQ ID NO:2;

(ii) exhibits at least one biological property in common with VEGF.

30

Another embodiment provides a recombinant molecule having the following characteristics:

- 6 -

(i) an amino acid sequence substantially as set forth in SEQ ID NO:10 or having at least about 15% similarity to all or part thereof provided that said amino acid sequence is at least about 5% dissimilar to all or part of the amino acid sequence set forth in SEQ ID NO:2;

5 (ii) exhibits at least one biological property in common with VEGF.

Such properties of VEGF include at least one of:

(a) ability to induce proliferation of vascular endothelial cells;

(b) an ability to interact with *flt-1/flk-1* family of receptors;

10 (c) an ability to induce cell migration, cell survival and/or an increase in intracellular levels of alkaline phosphatase.

In accordance with the present invention, a preferred similarity is at least about 40%, more preferably at least about 50% and even more preferably at least about 65%  
15 similarity.

Still a further aspect of the present invention contemplates a peptide fragment corresponding to a portion of the amino acid sequence set forth in SEQ ID NO:4 or a splice variant thereof such as set forth in SEQ ID NO:6, SEQ ID NO:8 or SEQ ID  
20 NO:10 or a chemical equivalent thereof. The biologically isolated or recombinant molecule of the present invention may be naturally glycosylated or may comprise an altered glycosylation pattern depending on the cells from which it is isolated or synthesised. For example, if produced by recombinant means in prokaryotic organisms, the molecule would be non-glycosylated. The molecule may be a full length, naturally  
25 occurring form or may be a truncated or otherwise derivatised form.

Yet another aspect of the present invention is directed to a nucleic acid molecule encoding the VEGF-like molecule herein described. More particularly, the present invention provides a nucleic acid molecule comprising a sequence of nucleotides  
30 substantially as set forth in SEQ ID NO:3 or having at least 15% similarity to all or part thereof or being capable of hybridising under low stringency conditions to a reverse complement of the nucleotide sequence as set forth in SEQ ID NO:3 provided that the

- 7 -

nucleic acid sequence having at least 15% similarity but at least 30% dissimilarity to the nucleotide sequence as set forth in SEQ ID NO:3. The nucleotide sequence set forth in SEQ ID NO:3 is also referred to herein as "SOM175". Preferably, the percentage dissimilarity is about 35%, more preferably about 39% and even more preferably about 5 40-50% or greater.

For the purposes of defining the level of stringency, reference can conveniently be made to Sambrook *et al* (1989) at pages 9.47-9.51 which is herein incorporated by reference where the washing steps disclosed are considered high stringency. A low stringency is 10 defined herein as being in 4-6X SSC/0.1-0.5% w/v SDS at 37-45°C for 2-3 hours. Depending on the source and concentration of nucleic acid involved in the hybridisation, alternative conditions of stringency may be employed such as medium stringent conditions which are considered herein to be 1-4X SSC/0.25-0.5% w/v SDS at  $\geq 45^{\circ}\text{C}$  for 2-3 hours or high stringent conditions considered herein to be 0.1-1X SSC/0.1% w/v 15 SDS at 60°C for 1-3 hours.

The present invention further contemplates a nucleic acid molecule which encodes a VEGF-like molecule as hereinbefore described having at least 15% nucleotide sequence homology to SEQ ID NO:3. Preferred levels of homology include at least about 40%. 20 more preferably around 60-70%.

The present invention is further directed to the murine homologue of human VEGF (referred to herein as "mVRF"). The mVRF has approximately 85% identity and 92% conservation of amino acid residues over the entire coding region compared to human 25 VEGF. The mVRF is encoded by a nucleic acid molecule comprising a nucleotide sequence substantially as set forth in Figure 9.

The VEGF-like molecule of the present invention will be useful in the development of a range of therapeutic and/or diagnostic applications alone or in combination with other 30 molecules such as VEGF. The present invention extends, therefore, to pharmaceutical compositions comprising the VEGF-like molecule or parts, fragments, derivatives, homologues or analogues thereof together with one or more pharmaceutically acceptable

carriers and/or diluents. Furthermore, the present invention extends to vectors comprising the nucleic acid sequence set forth in SEQ ID NO:3 or having at least about 15%, more preferably about 40% and even more preferably around 60-70% similarity thereto but at least 30% and more preferably around 39% dissimilarity thereto and host cells comprising same. In addition, the present invention extends to ribozymes and antisense molecules based on SEQ ID NO:3 as well as neutralizing antibodies to the VEGF-like molecule. Such molecules may be useful in ameliorating the effects of, for example, over expression of VEGF-like genes leading to angiogenesis or vascularization of tumours.

10

Another aspect of the present invention contemplates a method of inducing astroglial proliferation in a mammal, said method comprising administering to said mammal an effective amount of a recombinant proteinaceous molecule having the characteristics:

- 15 (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to the sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one property in common with vascular endothelial growth factor (VEGF),

20 said administration being for a time and under conditions sufficient to induce astroglial proliferation.

Preferably, the recombinant proteinaceous molecule comprises the amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:6.

25 A further aspect of the present invention provides a method of promoting neural survival and/or proliferation in a mammal, said method comprising administering to said mammal an effective amount of a recombinant proteinaceous molecule having the characteristics:

- 30 (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to the sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one property in common with vascular endothelial growth factor (VEGF),

- 9 -

said administration being for a time and under conditions sufficient to induce astroglial proliferation.

Preferably, the recombinant proteinaceous molecule comprises the amino acid sequence

5 set forth in SEQ ID NO:3 or SEQ ID NO:6.

The present invention also contemplates antibodies to the VEGF-like molecule or nucleic acid probes to a gene encoding the VEGF-like molecule which are useful as diagnostic agents.

10

The present invention is further described by reference to the following non-limiting Figures and/or Examples.

In the Figures:

15

**Figure 1** Nucleotide sequence [SEQ ID NO:1] and corresponding amino acid sequence [SEQ ID NO:2] of VEGF<sub>165</sub>.

20

**Figure 2** Nucleotide sequence [SEQ ID NO:3] and corresponding amino acid sequence [SEQ ID NO:4] of SOM175.

**Figure 3** Results of BLAST search with SOM175 protein sequence.

25

**Figure 4** BESTFIT alignment of VEGF cDNA and SOM175 cDNA.

**Figure 5** Multiple alignment of VEGF<sub>165</sub> with SOM175 and its splice variants at the nucleotide level.

30

**Figure 6** Multiple alignment of VEGF<sub>165</sub> with SOM175 and its splice variants at the amino acid level.

**Figure 7** Diagrammatic representation of SOM175 and its splice variants.

- 10 -

**Figure 8(a)** Diagrammatic representation of genomic structure of human SOM175 genomic showing exon/intron map.

**Figure 8(b)** Diagrammatic representation of genomic structure of human SOM175

5 showing exon/intron boundaries.

**Figure 9** Nucleotide and predicted peptide sequences derived from mVRF cDNA clones. Numbering of nucleotides are given on the left, starting from the A of the initiation codon. Amino acids are numbered on the right, starting from the first residue 10 of the predicted mature protein after the putative signal peptide has been removed. The alternately spliced region is double underlined and the resulting peptide sequence from each mRNA is included. A potential polyadenylation signal is indicated in boldface. Start and stop codons of mVRF<sub>167</sub> and mVRF<sub>186</sub> are underlined and a polymorphic AC repeat in the 3' UTR is indicated by a stippled box. The positions of intron/exons 15 boundaries are indicated by arrowheads.

**Figure 10** BESTFIT alignments of human and murine VRF protein isoforms. A: mVRF<sub>167</sub> and hVRF<sub>167</sub>. B: mVRF<sub>186</sub> and hVRF<sub>186</sub> from the point where the sequences diverge from the respective 167 amino acid isoforms. Amino acid identities are marked 20 with vertical bars and conserved amino acids with colons. An arrow marks the predicted signal peptide cleavage site of human and mouse VRF.

**Figure 11** BESTFIT alignment of mVRF<sub>167</sub> and mVEGF<sub>188</sub> (Breier *et al*, 1992) peptide sequences. An arrow marks the signal peptide cleavage site of mVEGF. 25 Identical amino acids are indicated by vertical bars and conservative substitutions by colons. Numbering of amino acids is as described in the legend to Figure 9.

**Figure 12** Comparison of gene structure between VRF (a generic VRF gene is shown since the intron/exon organisation of the mouse and human homologues is almost 30 identical) and other members of the human VEGF/PIGF/PDGF gene family. Exons are represented by boxes. Protein coding regions and untranslated regions are shown by filled and open sections respectively. The hatched region in VRF indicates the

additional 3' UTR sequence formed by alternate splicing of the VRF<sub>186</sub> isoform. Potential alternate splice products of each gene are shown.

5 **Figure 13** Autoradiogram of a Northern blot of total RNA from various adult mouse tissues (as indicated) hybridised with an mVRF cDNA clone. A major transcript of 1.3 kb was detected in all samples.

10 **Figure 14** Film autoradiographs (A-C) and dark-field micrographs (D-E) illustrating the expression pattern of mVRF and mRNA in the mouse. In the E14 mouse embryo (A) positive signals are present over the developing heart (Ha) and cerebral cortex (Cx). A low background signal is also present over other tissues in the section. In the E17 embryo (B) and the heart (Ha) is clearly visible due to a strong hybridisation signal. An 15 equally strong signal is present over brown adipose tissue (Fa) in the back and around the thoracic cage. A moderate hybridisation signal is present over the spinal cord (SC) and the tongue (T). The background signal is reduced compared with the E14 embryo. In the young adult mouse (C-D), positive signals are present over the heart (Ha) and 20 adipose tissue (Fa) around the thoracic cage, while, for example, the lungs (Lu) are unlabeled. The hybridisation signal over the heart is evenly distributed over the entire left ventricle, including papillary muscles (D). In the E17 heart hybridised with an excess of cold probe, no positive signal is present (E). Scale bars = 0.5 mm (A), 1.2 mm (B), 1 mm (C), 0.3 mm (D), 0.1 mm (E).

25 **Figure 15** Dark - (A and C) and bright-field (B and D) micrographs showing mVRF mRNA expression in mouse adipose tissue (A-B) and spinal cord (C-D). A strong hybridisation signal is present over fat (A), as shown by the strong labeling in Sudan black stained sections (B). A weak signal is present also in skeletal muscle (M in A-B). In the adult spinal cord (C) the mVRF probes gave a neuronal staining pattern over the gray matter. Toluidine counterstaining showing that motoneurons in the ventral horn (D), interneurons in the deep part of the dorsal horn and around the central canal (not 30 shown) where largely positive for mVRF mRNA. Scale bars = 0.1 mm (A), 0.1 mm (B), 0.25 mm (C), 0.015 mm (D).

- 12 -

**Figure 16** Effect of VEGF on embryonic day 8 (E8) chick sensory neurons as determined by % survival, % neurite outgrowth and average neurite length (μm).

**Figure 17** Effects of VEGF and SOM175 on chick glia. Tested were CNS glial, 5 peripheral glia and CNS oligodendrocytes.

**Figure 18** Effect of various SOM175 proteins on mouse astroglial cells. ■  $^3\text{H}$  (cpm)

1. FGF-2 (10 ng/ml) positive control
2. SOM $\Delta$ X6\* 1 ng/ml
- 10 3. SOM $\Delta$ X6 10 ng/ml
4. SOM $\Delta$ X6 100 ng/ml
5. SOM $\Delta$ X6 1000 ng/ml
6. SOM $\Delta$ X6 1000 ng/ml, no heparin
7. SOMX6\*\* 1 ng/ml
- 15 8. SOMX6 10 ng/ml
9. SOMX6 100 ng/ml
10. SOMX6 1000 ng/ml
11. SOMX6 1000 ng/ml, no heparin

\* This refers to SOM175 absent exon 6;

20 \*\* This refers to SOM175.

**Figure 19** Effect of various SOM175 proteins on mouse oligodendroglial cells. ■  $^3\text{H}$

(cpm)

1. FGF-2 (10 ng/ml) positive control
- 25 2. SOM $\Delta$ X6\* 1 ng/ml
3. SOM $\Delta$ X6 10 ng/ml
4. SOM $\Delta$ X6 100 ng/ml
5. SOM $\Delta$ X6 1000 ng/ml
6. SOM $\Delta$ X6 1000 ng/ml, no heparin
- 30 7. SOMX6\*\* 1 ng/ml
8. SOMX6 10 ng/ml
9. SOMX6 100 ng/ml

- 13 -

10. SOMX6 1000 ng/ml
11. SOMX6 1000 ng/ml, no heparin

\* This refers to SOM175 absent exon 6;

\*\* This refers to SOM175.

5

**Figure 20** Effect of various SOM175 proteins on mouse forebrain neurons. ■ % survival

1. FGF-2 (10 ng/ml) positive control
2. SOM $\Delta$ X6\* 1 ng/ml
- 10 3. SOM $\Delta$ X6 10 ng/ml
4. SOM $\Delta$ X6 100 ng/ml
5. SOM $\Delta$ X6 1000 ng/ml
6. SOM $\Delta$ X6 1000 ng/ml, no heparin
7. SOMX6\*\* 1 ng/ml
- 15 8. SOMX6 10 ng/ml
9. SOMX6 100 ng/ml
10. SOMX6 1000 ng/ml
11. SOMX6 1000 ng/ml, no heparin

\* This refers to SOM175 absent exon 6;

20 \*\* This refers to SOM175.

TABLE 1  
SUMMARY OF SEQUENCE IDENTITY NUMBERS

---

5	SEQ ID NO:1	Nucleotide sequence of VEGF <sub>165</sub>
	SEQ ID NO:2	Amino acid sequence of VEGF <sub>165</sub>
	SEQ ID NO:3	Nucleotide sequence of SOM175 (VEGF-like molecules)
	SEQ ID NO:4	Amino acid sequence of SOM175
10	SEQ ID NO:5	Nucleotide sequence of SOM175 absent exon 6
	SEQ ID NO:6	Amino acid sequence of SOM175 absent exon 6
	SEQ ID NO:7	Nucleotide sequence of SOM175 absent exon 6 and exon 7
	SEQ ID NO:8	Amino acid sequence of SOM175 absent exon 6 and exon 7
	SEQ ID NO:9	Nucleotide sequence of SOM175 absent exon 4
15	SEQ ID NO:10	Amino acid sequence of SOM175 absent exon 4
	SEQ ID NO:11	Oligonucleotide
	SEQ ID NO:12	Oligonucleotide
	SEQ ID NO:13	Oligonucleotide
	SEQ ID NO:14	Oligonucleotide
20		

---

### EXAMPLE 1

#### **Human cDNA clones**

The original SOM175 cDNA was isolated by screening a human foetal brain library 25 ( $\lambda$ zapII, Stratagene) with the cosmid D11S750 (Larsson *et al*, 1992). The plasmid was excised "in vivo" and a single 1.1kb cDNA was obtained. Three independent SOM175 cDNAs clones were also isolated from a human foetal spleen library (Stratagene, Uni-zap) using the above-mentioned SOM175 insert as a probe. Three clones were obtained: SOM175-4A, -5A and -6A. SOM175-5A is an alternately spliced clone with exon 4 30 being absent (SOM175-e4). These library screens were performed using hybridisation conditions recommended by the manufacturer of the library (Stratagene) and random primed insert of SOM175.

- 15 -

Two partial human SOM175 cDNAs have also isolated from a  $\lambda$ GT11 human melanoma cell line A2058 library (Clontech) cDNA library screens were performed using hybridisation conditions described by Church and Gilbert, 1984). In each case, the probe was generated by random priming of a PCR product derived from SOM175 (18f-5 700r).

#### Mouse cDNA Clones

Human SOM175 was also used to screen a mouse neonatal whole brain cDNA library (Unizap, Stratagene). Four non-chimeric clones were isolated: M175-A, B, C, D. All 10 clones were partial cDNAs and M175-C contained several introns. Three of these cDNAs lacked the exon 6.

Another clone referred to as M1 was completely sequenced and was found to contain the full open reading frame plus part of the 5'utr and total 3'utr.

15

#### EXAMPLE 2

#### DNA SEQUENCE ANALYSIS

The entire sequence of the cDNA clone (SOM175) was compiled and is shown in Figure 2 with its corresponding amino acid sequence. This sequence was screened for 20 open reading frames using the MAP program (GCG, University of Wisconsin). A single open reading frame of 672bp was observed (see Figure 2). There appears to be little 5' untranslated sequences (2bp). The 3' untranslated region appears to be complete as it includes a poly-adenylation signal and poly-A tail.

25 Database homology searches were performed using the BLAST algorithm (run at NCBI, USA). This analysis revealed homology to several mammalian forms of VEGF (see Figure 3). The amount of homology between SOM175 and human VEGF<sub>165</sub> was determined using the BESTFIT program (GCG, University of Wisconsin; see Figures 4 and 5). Nucleotide homology was estimated at 69.7% and protein homology was 30 estimated as at least 33.3% identity and 52.5% conservation using BESTFIT analysis. BLAST analysis on nucleotide sequences revealed the almost complete match to a human expressed sequence tag EST06302 (Adams *et al.*, 1993).

- 16 -

These data indicate that SOM175 encodes a growth factor that has structural similarities to VEGF. Both genes show start and stop codons in similar positions and share discrete blocks of homology. All 8 cysteines as well as a number of other VEGF residues believed to be involved in dimerisation are conserved. These residues are Cysteine-47, 5 Proline-70, Cysteine-72, Valine-74, Arginine-77, Cysteine-78, Glycine-80, Cysteine-81, Cysteine-82, Cysteine-89, Proline-91, Cysteine-122 and Cysteine-124 and are shown in Figure 6. Given the structural conservation between VEGF and the SOM175 gene product it is also possible that they share functional similarities. It is proposed that 10 SOM175 encodes a VEGF-like molecule that shares some properties with VEGF but has unique properties of its own. The nucleotide sequence and corresponding amino acid sequence of VEGF<sub>165</sub> is shown in Figure 1.

### EXAMPLE 3

The percentage similarity and divergence between VEGF<sub>165</sub> family and SOM175 family 15 (protein) were analysed using the Clustal method, MegAlign Software, DNASTAR, Wisconsin. The results are shown in Tables 2.1 and 2.2. The alternatively spliced forms of SOM175 are abbreviated to SOM715-e6 where all of exon 6 is deleted; SOM715-e6 and 7 where all of exons 6 and 7 are deleted; and SOM175-e4 where all of exon 4 is deleted. The spliced form of SOM175 are shown in Figure 7. Genomic 20 maps of SOM175 showing intron/exon boundaries are shown in Figure 8a and 8b.

**Table 2.1**

5      **A      Percent nucleotide similarity between splice variants of SOM175 and**  
**human VEGF<sub>165</sub>**

	VEGF <sub>165</sub>	SOM175	SOM175-e6	SOM175-e6&7	SOM175-e4
	VEGF <sub>165</sub>	***	34.9	39.7	41.4
10	SOM175		***	98.9	95.1
	SOM175-e6			***	98.8
	SOM175-e6&7				***
	SOM175-e4				84.0
					80.3
					***

**B Percent nucleotide divergence between splice variants of SOM175 and human VEGF<sub>165</sub>**

5		VEGF <sub>165</sub>	SOM175	SOM175-e6	SOM175-e6&7	SOM175-e4
	<b>VEGF<sub>165</sub></b>	***	41.7	41.6	41.7	41.8
	<b>SOM175</b>		***	0.2	0.2	0.0
	<b>SOM175-e6</b>			***	0.0	0.2
10	<b>SOM175-e6&amp;7</b>				***	0.3
	<b>SOM175-e4</b>					***

**Table 2.2**

**A Percent amino acid identity between splice variants of SOM175 and human VEGF<sub>165</sub>**

		VEGF <sub>165</sub>	SOM175	SOM175-e6	SOM175-e6&7	SOM175-e4
20	<b>VEGF<sub>165</sub></b>	***	31.4	42.3	33.5	40.6
	<b>SOM175</b>		***	74.7	73.7	99.1
	<b>SOM175-e6</b>			***	76.8	99.1
	<b>SOM175-e6&amp;7</b>				***	99.1
	<b>SOM175-e4</b>					***
25						

**B Percent amino acid divergence between splice variants of SOM175 and human VEGF<sub>165</sub>**

5		VEGF <sub>165</sub>	SOM175	SOM175-e6	SOM175-e6&7	SOM175-e4
	VEGF <sub>165</sub>	***	65.7	55.4	54.6	57.4
	SOM175		***	19.9	4.2	0.0
	SOM175-e6			***	0.0	0.0
10	SOM175-e6&7				***	0.0
	SOM175-e4					***

15 **EXAMPLE 4**

**BIOASSAYS TO DETERMINE THE FUNCTION OF SOM175**

Assays are conducted to evaluate whether SOM175 has similar activities to VEGF on endothelial cell function, angiogenesis and wound healing. Other assays are performed based on the results of receptor binding distribution studies.

20

**Assays of endothelial cell function**

*Endothelial cell proliferation.* Endothelial cell growth assays as described in Ferrara & Henzel (1989) and in Gospodarowicz *et al* (1989).

25 *Vascular permeability assay.* This assay, which utilises the Miles test in guinea pigs, will be performed as described in Miles & Miles (1952).

*Cell adhesion assay.* The influence of SOM175 on adhesion of polymorphs to endothelial cells is analysed.

30

*Chemotaxis.* This is performed using the standard Boyden chamber chemotaxis assay.

- 20 -

*Plasminogen activator assay.* Endothelial cells are tested for plasminogen activator and plasminogen activator inhibitor production upon addition of SOM175 (Pepper *et al* (1991)).

5 *Endothelial cell migration assay.* The ability of SOM175 to stimulate endothelial cells to migrate and form tubes is assayed as described in Montesano *et al* (1986).

#### **Angiogenesis Assay**

SOM175 induction of an angiogenic response in chick chorioallantoic membrane is  
10 evaluated as described in Leung *et al* (1989).

Possible neurotrophic actions of SOM175 are assessed using the following assays:

#### **Neurite outgrowth assay and gene induction (PC12 cells)**

15 PC12 cells (a phaeochromocytoma cell line) respond to NGF and other neurotrophic factors by developing the characteristics of sympathetic neurons, including the induction of early and late genes and the extension of neurites. These cells are exposed to SOM175 and their response monitored (Drinkwater *et al* (1991); and Drinkwater *et al* (1993)).

20

#### **Cultured neurons from the Peripheral Nervous System (PNS)**

Primary cultures of the following PNS neurons are exposed to SOM175 and monitored for any response:

- sensory neurons from neural crest and dorsal root ganglia
- sympathetic neurons from sympathetic chain ganglia
- placode derived sensory neurons from nodose ganglia
- motoneurons from spinal cord

The assays are described in Suter *et al* (1992) and in Marinou *et al* (1992).

30 Where an *in vitro* response is observed, *in vivo* assays for properties such as uptake and retrograde transport are performed as described in Hendry *et al* (1992).

- 21 -

### **Nerve regeneration (PNS)**

Where neurotrophic effects of SOM175 are observed, its possible role in the regeneration of axotomised sensory neurons, sympathetic neurons and motoneurons is analysed by the methods of Otto *et al* (1989); Yip *et al* (1984) and Hendry *et al* 5 (1976).

### **Actions of SOM175 on CNS neurons**

The ability of SOM175 to promote survival of central nervous system neurons is analysed as described in Hagg *et al* (1992); Williams *et al* (1986); Hefti (1986) and 10 Kromer (1987).

### **Wound Healing**

The ability of SOM175 to support wound healing are tested in the most clinically relevant model available, as described in Schilling *et al* (1959) and utilised by Hunt 15 *et al* (1967).

### **The Haemopoietic System**

A variety of *in vitro* and *in vivo* assays on specific cell populations of the haemopoietic system are available and are outlined below:

20 **Stem Cells**

*Murine*

A variety of novel *in vitro* murine stem cell assays have been developed using FACS-purified cells:

25 **(a) Repopulating Stem Cells**

These are cells capable of repopulating the bone marrow of lethally irradiated mice, and have the Lin<sup>-</sup>, Rh<sup>hi</sup>, Ly-6A/E<sup>+</sup>, c-kit<sup>+</sup> phenotype. The test substance is tested on these cells either alone, or by co-incubation with multiple factors, followed by measurement of cellular proliferation by <sup>3</sup>H thymidine incorporation.

**(b) Late Stage Stem Cells**

These are cells that have comparatively little bone marrow repopulating ability but can generate D13 CFU-S. These cells have the Lin<sup>-</sup>, Rh<sup>hi</sup>, Ly-6A/E<sup>+</sup>, c-kit<sup>+</sup> phenotype. The test substance is incubated with these cells for a period of time, injected into lethally irradiated recipients, and the number of D13 spleen colonies enumerated.

5

**(c) Progenitor-Enriched Cells**

10 These are cells that respond *in vitro* to single growth factors, and have the Lin<sup>-</sup>, Rh<sup>hi</sup>, Ly-6A/E<sup>+</sup>, c-kit<sup>-</sup> phenotype. This assay will show if SOM175 can act directly on haemopoietic progenitor cells. The test substance is incubated with these cells in agar cultures, and the number of colonies enumerated after 7-14 days.

15 **Atherosclerosis**

Smooth muscle cells play a crucial role in the development or initiation of atherosclerosis, requiring a change in their phenotype from a contractile to a synthetic state. Macrophages, endothelial cells, T lymphocytes and platelets all play a role in the development of atherosclerotic plaques by influencing the growth and phenotypic modulations of smooth muscle cell. An *in vitro* assay that measures the proliferative rate and phenotypic modulations of smooth muscle cells in a multicellular environment is used to assess the effect of SOM175 on smooth muscle cells. The system uses a modified Rose chamber in which different cell types are seeded onto opposite coverslips.

20

25

**Effects of SOM175 on bone**

The ability of SOM175 to regulate proliferation of osteoblasts is assayed as described in Lowe *et al* (1991). Any effects on bone resorption are assayed as described in Lowe *et al* (1991). Effects on osteoblast migration and changes in intracellular molecules (e.g. cAMP accumulation, alkaline phosphatase levels) are analysed as described in Midy *et al* (1994).

30

**Effects on skeletal muscle cells**

Effects of SOM175 on proliferation of myoblasts and development of myotubes can be determined as described by Ewton *et al* (1980) and by Gospodarowicz *et al* (1976).

5

**EXAMPLE 5**  
**CLONING MURINE VEGF DNA****Isolation of cDNAs**

Murine VRF (mVRF) clones were selected from a lambda Zap new born whole brain 10 cDNA library (Stratagene). Primary phage from high density filters ( $5 \times 10^4$  pfu/plate) were identified by hybridisation with a 682bp  $^{32}\text{P}$ -labelled probe generated by PCR from an hVRF cDNA (pSOM175) as described above. Hybridisation and stringent washes of nylon membranes (Hybond-N) were carried out at 65°C under conditions described by Church and Gilbert (1984). Positive plaques were picked, 15 purified and excised *in vivo* to produce bacterial colonies containing cDNA clones in pBluescript SK-.

**Isolation of genomic clones**

Genomic clones were isolated from a mouse strain SV/129 library cloned in the 20 lambda Fix II vector (Stratagene). High density filters ( $5 \times 10^4$  pfu/filter) were screened with a 563 bp  $^{32}\text{P}$ -labelled probe generated by PCR amplification of the nucleotide 233-798 region of the mVRF cDNA (see Figure 9). Positive clones were plugged and re-screened with filters containing 400-800 pfu. Large scale phage preparations were prepared using the QIAGEN lambda kit or by  $\text{ZnCl}_2$  purification 25 (Santos, 1991).

**Nucleotide sequencing and analysis**

cDNAs were sequenced on both strands using a variety of vector-based and internal primers with Applied Biosystems Incorporated (ABI) dye terminator sequencing kits 30 according to the manufacturer's specifications. Sequences were analysed on an ABI Model 373A automated DNA sequencer. Peptide homology alignments were performed using the program BESTFIT (GCG, Wisconsin).

- 24 -

#### **Identification of intron/exon boundaries**

Identification of exon boundaries and flanking regions was carried out using PCR with mouse genomic DNA or mVRF genomic lambda clones as templates. The primers used in PCR to identify introns were derived from the hVRF sequence and to

5 allow for potential human-mouse sequence mismatches annealing temperatures 5-10°C below the estimated  $T_m$  were used. All PCR products were sized by agarose gel electrophoresis and gel purified using QIAquick spin columns (Qiagen) and the intron/exon boundaries were sequenced directly from these products. In addition, some splice junctions were sequenced from subcloned genomic fragments of MVRF.

10 Intron/exon boundaries were identified by comparing cDNA and genomic DNA sequences.

#### **Northern analysis**

Total cellular RNA was prepared from a panel of fresh normal adult mouse tissues

15 (brain, kidney, liver, muscle) using the method of Chomczynski and Sacchi (1987). 20 $\mu$ g of total RNA were electrophoresed, transferred to a nylon membrane (Hybond N, Amersham) and hybridised under standard conditions (Church & Gilbert, 1984). Filters were washed at 65°C in 0.1xSSC (20xSSC is 3M NaCl/0.3M trisodium citrate), 0.1% SDS and exposed to X-ray film with intensifying screens at -70°C for

20 1-3 days.

#### **Characterisation of mVRF cDNAs**

Murine VRF homologues were isolated by screening a murine cDNA library with an hVRF cDNA clone. Five clones of sizes varying from 0.8-1.5 kb were recovered

25 and sequenced. The cDNA sequences were complied to give a full length 1041 bp cDNA sequence covering the entire open reading frame (621 bp or 564 bp depending on the splice form, see below) and 3' UTR (379 bp), as well as 163 bp of the 5' UTR (Figure 9).

30 The predicted initiation codon matched the position of the start codon in hVRF. One other out of frame ATG was located at position -47 and two termination codons were observed upstream (positions -9 and -33, respectively) and in-frame with the putative

initiation codon.

The predicted N-terminal signal peptide of hVRF appears to be present in mVRF with 81% identity (17/21 amino acids). Peptide cleavage within mVRF is expected 5 to occur after residue 21 (Figure 10). These data suggest that mature mVRF is secreted and could therefore conceivably function as a growth factor.

As with hVRF, two open reading frames (ORFs) were detected in cDNAs isolated by library screening. Four of five clones were found to be alternatively spliced and 10 lacked a 101 bp fragment homologous to exon 6 of hVRF. The predicted peptide sequences of the two isoforms of mVRF were determined and aligned with the corresponding human isoforms (Figure 10).

The message encoding mVRF<sub>186</sub> contains a 621 bp ORF with coding sequences 15 terminating at position +622, towards the end of exon 7 (Figure 9). The smaller message encoding mVRF<sub>167</sub> actually terminates downstream of the +622 TAG site due to a frame shift resulting from splicing out of the 101 bp exon 6 and the introduction of a stop codon (TGA) at position +666, near the beginning of exon 8 (Figure 9).

20

The mVRF<sub>186</sub> protein has strong homology to the amino and central portions of VEGF while the carboxyl end is completely divergent and is alanine rich. mVRF<sub>167</sub> possesses these similarities and also maintains homology to mVEGF right through to the C-terminus (Figure 11). The overall homology of mVRF<sub>167</sub> to hVRF<sub>167</sub> was 25 85% identity and 92% similarity, respectively (Figure 10). Likewise, homology between mVRF<sub>167</sub> and mVEGF (Breier *et al*, 1992) was 49% identity and 71% conservative amino acid substitution, respectively (Figure 11).

A canonical vertebrate polyadenylation signal (AATAAA) (Birnstiel *et al*, 1986) was 30 not present in the mVRF cDNA, however, the closely matching sequence GATAAA is present at similar positions in both mouse and human VRF cDNAs (Figure 9). In contrast to hVRF, mVRF was found to contain an AC dinucleotide repeat at the

- 26 -

extreme 3' end of the 3' UTR (nucleotide positions 998 to 1011, Figure 9).

Polymorphism of this repeat region was observed between some of the mVRF cDNAs, with the number of dinucleotides varying from 7 to 11.

## 5 Genomic characterisation of mVRF

Intron/exon boundaries (Table 3) were mapped using primers which flanked sequences homologous to the corresponding hVRF boundaries. Introns I, III, IV and VI of mVRF (Table 3, Figure 12) were smaller than the hVRF intervening sequences. The complete genomic sequence was compiled from the 5' UTR of mVRF through to intron VI, the largest intervening region (2.2 kb), by sequencing amplified introns and cloned genomic portions of mVRF. There was only one major difference in genomic structure between mVRF and hVRF and that was the exon 7/intron VI boundary of mVRF was located 10bp further downstream in relation to the cDNA sequence, hence exon 7 in mVRF is 10bp longer than the corresponding exon in hVRF.

Exons 6 and 7 are contiguous in mVRF, as has been found to occur in the human homologue. The strong sequence homology between exon 6 of mVRF and hVRF (Figure 10) suggests that this sequence is not a retained intronic sequence but rather encodes a functional part of the VRF<sub>186</sub> isoform.

General intron/exon structure is conserved between the various members of the VEGF gene family (VEGF, PIGF, hVRF) and therefore it is not surprising that the overall genomic organisation of the mVRF gene is very similar to these genes (Figure 12).

Previous comparative mapping studies have shown that the region surrounding the human multiple endocrine neoplasia type 1 disease locus on chromosome 11q13 is syntenic with the proximal segment of mouse chromosome 19 (Rochelle *et al*, 1992). Since the inventors have mapped the hVRF gene to within 1kb of the human *MEN1* locus (see above) it is most likely that the murine VRF gene maps near the centromere of chromosome 19.

**Expression studies of mVRF**

Northern analysis of RNA from adult mouse tissues (muscle, heart, lung and liver) showed that expression appears to be ubiquitous and occurs primarily as a major band of approximately 1.3kb in size (Figure 14). This is somewhat different to the 5 pattern observed for hVRF in which two major bands of 2.0 and 5.5 kb have been identified in all tissues examined. The 1.3 kb murine message presumably corresponds to the shorter of the human transcripts and the size variation thereof is most likely due to a difference in the length of the respective 5' UTRs.

10

**EXAMPLE 6****EXPRESSION OF MURINE VEGF IN PRE- AND POST-NATAL MOUSE****Animals**

Timed pregnant (n=4) and young adult (n=2) mice (C57 inbred strain, ALAB, Sweden) were sacrificed with carbon dioxide, and the relevant tissues were taken out 15 and frozen on a chuck. Tissues were kept at -70°C until further use. Two gestational ages was used in this study; embryonic day 8 (E8), 14 and E17.

***In situ* hybridisation histochemistry**

*In situ* hybridisation was performed as previously described (Dagerlind *et al*, 1992).

20 Briefly, transverse sections (14µm) were cut in a cryostat (Microm, Germany), thawed onto Probe-On slides (Fisher Scientific, USA) and stored in black sealed boxes at -70°C until used. The sequences of the synthetic 42-mer oligonucleotides complementary to mRNA encoding mVRF were

ACCACCACCTCCCTGGGCTGGCATGTGGCACGTGCATAAACG [SEQ ID

25 NO:11] (complementary to nt 120-161) and

AGTTTTGACCACATTGCCATGAGTTCCATGCTCAGAGGC [SEQ ID

NO:12] (complementary to nt 162-203). To detect the two alternative splice forms

oligonucleotide GATCCTGGGCTGGAGTGGATGGATGATGTCAGCTGG [SEQ

30 ID NO:13] (complementary to nt xxx-xxx) and

GCAGAGGATCCTGGGCTGTCTGGCCTCACAGCACT [SEQ ID NO:14]

were used. The probes were labeled at the 3'-end with deoxyadenosine-

alpha[thio]triphosphate [<sup>35</sup>S] (NEN, USA) using terminal deoxynucleotidyl

transferase (IBI, USA) to a specific activity of  $7-10 \times 10^8$  cpm/ $\mu$ g and hybridised to the sections without pretreatment for 16-18 h at 42°C. The hybridisation mixture contained: 50% v/v formamide, 4 x SSC (1 x SSC = 0.15M NaCl and 0.015M sodium-citrate), 1 x Denhardt's solution (0.02% each of polyvinyl-pyrrolidone, BSA and Ficoll), 1% v/v sarcosyl (N-lauroylsarcosine; Sigma), 0.02M phosphate buffer (pH 7.0), 10% w/v dextran sulfate (Pharmacia, Sweden), 250 $\mu$ g/ml yeast tRNA (Sigma), 500 $\mu$ g/ml sheared and heat denatured salmon sperm DNA (Sigma) and 200mM dithiothreitol (DTT; LKB, Sweden). In control sections, the specificity of both probes was checked by adding a 20-fold excess of unlabeled probe to the hybridisation mixture. In addition, adjacent sections were hybridised with a probe unrelated to this study which gave a different expression pattern. Following hybridisation the sections were washed several times in 1 x SSC at 55°C, dehydrated in ethanol and dipped in NTB2 nuclear track emulsion (Kodak, USA). After 3-5 weeks the sections were developed in D-19 developer (Kodak, USA) and cover-slipped. In some cases, sections were opposed to an autoradiographic film (Beta-max autoradiography film Amersham Ltd, UK) prior to emulsion-dipping.

The four different probes gave identical hybridisation patterns in all tissues examined. Mouse VRF expression was detected already in the E8 embryo, in which positive signal was recorded over structures most likely corresponding to the neuronal tube. In sagittal sections of E14 mouse embryo the strongest hybridisation signal was present over heart and in the nervous system, especially cerebral cortex (Figure 14A). A low level of expression was present in all other tissues. At a later gestational age, E17, a high mVRF mRNA signal was confined to the heart and brown fat tissue in the back and around the neck (Figure 14B). Clearly positive hybridisation signals were present in the gray of the spinal cord and in the tongue (Figure 14B). Expression in the cerebral cortex was clearly reduced compared to day 14. The weak background expression seen in the E14 embryo in for example muscle, had decreased at this gestational age. A strong mVRF mRNA hybridisation signal was present solely over the heart and in the brown fat in the young adult mice (Figure 14C). The signal over the heart was evenly distributed over the entire ventricular wall, including the papillary muscles (Figure 14D). In sections of heart tissue hybridised with an

- 29 -

excess of cold probe, no specific labeling over background signal was recorded (Figure 14E).

Apart from the heart, mVRF mRNA signal was present over certain tissues on the  
5 outside of the thoracic cage that morphologically resembled brown fat. This was  
verified with sudan black counterstaining, which showed a strong staining in the  
same areas (Figure 15A and 15B). In transverse sections of adult mouse spinal cord,  
the mVRF probes gave a neuronal staining pattern over the gray matter (Figure 15C).  
Counterstaining with toluidine (Figure 15D) showed that motoneurons in the ventral  
10 horn (Figure 15C and 15D), interneurons (Figure 15C) in the deep part of the dorsal  
horn and around the central canal where to a large extent positive for mVRF mRNA.

#### EXAMPLE 7

#### EFFECTS OF VEGF AND SOM175 PROTEINS ON CHICK SENSORY NEURONS

The effects of VEGF and SOM175 proteins on embryonic day 8 chick sensory  
neurons were determined using the method of Nurcombe *et al* (1992). The neuronal  
assay was read at 48 hours using 2000 cells per assay well. The results were  
obtained using  $^3$ H-thymidine counts. The percentage survival of neurons, neurite  
20 outgrowth and average neurite length in  $\mu$ m were determined using NGF as positive  
control and various concentrations of VEGF, VEGF in the presence of heparin and  
VEGF in the presence of heparin and 5  $\mu$ M, 5'-flurouracil (5FU). 5FU kills glial  
cells.

25 The results are shown in Figure 16. The results show that VEGF is effective in  
promoting neuronal survival but that this requires the presence of glial cells. Figure  
17 shows the results of the effect of VEGF and SOM175 on three types of chick  
glia. The glia tested were CNS glia, peripheral glia and CNS oligodendrocytes.  
Heparin was used as 10  $\mu$ g/ml in all cultures and the assay was read at 24 hours.  
30 Results were measured in  $^3$ H-thymidine counts using 2000 cells per well.

The results show that for chick central and peripheral neurons, astroglia were markedly stimulated to proliferate by SOM175 in the presence of heparin but that chick oligodendrocytes showed negligible increase in the rate of division.

5

#### EXAMPLE 8

#### EFFECTS OF SOM175 PROTEINS ON MOUSE PRIMARY AND CENTRAL NEURONS

The results in Example 7 show that VEGF isoform had an effect on chick primary  
10 and central neurons through the agency of the astroglial cells. Similar experiments  
were repeated in mouse cells.

##### Culture conditions

Neuronal and glial cells for all *in vitro* experiments were prepared and cultured  
15 according to the techniques described in "Methods in Neurosciences (Vol. 2): Cell  
Culture" Ed. P.M. Conn, Academic Press, San Diego, 1990, pp33-46 for astroglial  
cells, pp56-74 for oligodendroglial cells, and pp87-102 for central neurons.

Cells were plated onto 24-well culture clusters (Nunc) coated with poly-L-ornithine  
20 (0.1 mg/ml, 1h) at a density of 2,000 cells/well. After 48 hours in culture, neurons  
were counted in the wells under inverted phase light using well established  
techniques (Maruta *et al.* 1993) and glial cells assessed with [<sup>3</sup>H]thymidine uptake to  
monitor cell division rates as below. Heparin (10 $\mu$ g/ml, low molecular weight  
fraction, Sigma Chemical Corp.) was present at all times in the culture media except  
25 where noted. The neuronal cultures were supplemented with 5mM 5-fluoro-2-  
deoxyuridine (Sigma) to suppress background glial growth.

##### <sup>3</sup>H-Thymidine incorporation assay for glial cell proliferation

The cells were pulsed for 14h with <sup>3</sup>H-thymidine (specific activity 103  $\mu$ Ci/ug) from  
30 a stock concentration of 0.1 mCi/ml in standard medium, giving a final incubating  
volume of 20  $\mu$ l/well. The contents of the wells were harvested and absorbed onto  
nitrocellulose paper (Titertek, Flow). Remaining adherent cells were removed by

incubation with trypsin/versene (CSL Limited, Victoria, Australia) for 5 min. This procedure was carried out twice. The nitrocellulose discs were washed in a standard Titertek harvester (Flow) using first distilled water, and then methanol. The nitrocellulose discs were dried, scintillation fluid (containing 5% v/v Triton-X) added 5 and the discs counted on a scintillation counter.

Greatest activity was seen with preparations of SOM175 absent exon 6 (SOM $\Delta$ X6)

on mouse astroglial cell cultures, where there was a significant stimulus to their proliferation when delivered in conjunction with heparin (Figure 16). Little stimulus

10 was given to the proliferation of oligodendroglial cells (Figure 17), and very little discernable potentiation of the survival response of isolated forebrain neurons (Figure 18). The standard deviation on all three graphs for each point was less than 8%.

The viability of neurons can be maintained by promoting glial cell proliferation.

15 Furthermore, SOM $\Delta$ X6 is a good inducer of astroglial proliferation and may be expressed in conjunction with the formation of astroglial endfeet on central nervous system endothelial cells.

Those skilled in the art will appreciate that the invention described herein is

20 susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications.

The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

**TABLE 3**  
**Splice junctions of the murine VRF gene**

5	5' UTR* .....	Exon 1 >223bp	CCCAAGgtacgtgcgt	Intron I	495bp
	ttccccacagGCC	Exon 2 43bp	GAAAGgtataata	Intron II	288bp
	ctgcccacagTGG	Exon 3 197bp	TGCAGgtaccagg	Intron III	196bp
	ctgagcacagATC	Exon 4 74bp	TGCAGgtgccag	Intron IV	182bp
	ctctttcagACCT	Exon 5 36bp	GACAGAttcttgt	Intron V	191bp
10	ctcctcttagGGTT	Exon 6 101bp		(no intron)	
	CCCACTCCAGGCC	Exon 7 135bp	TGTAGgtaggagtc	Intron VI	~2200bp
	cactccccagGTGCC	Exon 8 394bp	AGAGATGGAGACACT		

Uppercase and lowercase letters denote exonic and intronic sequences respectively.

15 \* Indicates that the 5' end of exon 1 has not yet been determined.

## BIBLIOGRAPHY

Adams MD, Soares MB, Kerlavage AR, Fields C, Venter JC, (1993) *Nature Genet.* **4**, 373-380.

Birnstiel ML, Busslinger M and Strub K (1985) *Cell* **41**, 349-359.

Breier G, Albrecht U, Sterrer S and Risau W (1992) *Development* **114**, 521-532.

Chomczynski P and Sacchi N (1987) *Analyt. Biochem.* **162**, 156-159.

Church G and Gilbert W (1984) *Proc. Natl. Acad. Sci. USA* **81**, 1991-1995.

Dagerlind A, Friberg K, Bean AJ and Hokfelt T (1992) *Histochemistry* **98**, 39-49.

Dissen GA, Lara HE, Fabrenbach WH, Costa ME, Ojeda SR, (1994) *Endocrinology* **134**, 1146-1154.

Drinkwater CC, Barker PA, Suter U and Shooter EM (1993) *J. Biol. Chem.*, **268**, 23202-23207.

Drinkwater CC, Suter U, Angst C and Shooter EM (1991) *Proc. Roy. Soc. Lond. (Series B)*, **246**, 307-313.

Ewton DZ & Florini JR (1980) *Endocrinology*, **106**: 577-583.

Ferrara N & Henzel WJ (1989) *Biochem. Biophys. Res. Commun.* **161**, 851-858.

Folkman J & Shing Y (1992) *J. Biol. Chem.* **267**, 10931-10934.

Gospodarowicz D, Abraham JA & Schilling J (1989) *Proc. Natl. Acad. Sci USA* **86**, 7311-7315.

Gospodarowicz D, Weseman J, Morgan JS & Lindstrom J (1976) *J. Cell Biol.*, **70**: 395-405.

Hagg T, Quon D, Higaki J & Varon S (1992) *Neuron*, **8**, 145-158.

Hefti S (1986) *J. Neurosci.*, **6**, 2155-2162.

Hendry IA & Campbell J (1976) *J. Neurocytol.*, **5**, 351-360.

Hendry IA, Murphy M, Hilton DJ, Nicola NA & Bartlett PF (1992) *J. Neurosci.* **12**, 3427-3434.

Hunt *et al.*, (1967) *Am. J. Surgery*, **114**: 302-307.

Koch AE, Harlow LA, Haines GK, Amento EP, Unemoto EN, Wong WL, Pope RM, Ferrara N, (1994) *J. Immunol.* **152**, 4149-4156.

Kromer AF (1987) *Science*, **235**, 214-216.

- 34 -

Larsson C, Weber G, Kvanta E, Lewis C, Janson M, Jones C, Glaser T, Evans G, Nordenskjold M, (1992) *Hum. Genet.* **89**, 187-193.

OZUS Leung DW, Cachianes G, Kuang W-J, Goeddel DV & Ferrara N (1989) *Science* **246**:1306-1309.

Lowe C, Cornish J, Callon K, Martin TJ & Reid IR (1991) *J. Bone Mineral Res.*, **6**, 1277-1283.

Lowe C, Cornish J, Martin TJ & Reid IR (1991) *Calcif. Tissue Int.*, **49**, 394-397.

Martinou JC, Martinou I & Kato AC (1992) *Neuron*, **8**, 737-744.

Maruta *et al* (1993) *Growth Factors* **8**: 119-134.

Midy V & Plouet J (1994) *Biochem. Biophys. Res. Commun.*, **199**: 380-386.

Miles AA & Miles EM (1952) *J. Physiol. (Lond)* **118**:228-257.

Montesano R, Vassalli JD, Baird A, Guillemain R & Orci, L (1986) *Proc. Natl. Acad. Sci USA*, **83**, 7297-7301.

Nurcombe *et al* (1992) *Development* **116**: 1175-1183.

Otto D., Frotscher M & Unsicker K (1989) *J. Neurosci. Res.*, **22**, 83-91.

Pepper MS, Ferrara N, Orci L, Montesano R. (1991) *Biochem. Biophys. Res. Commun.* **181**, 902-906.

Rochell JM, Watson ML, Oakey RJ and Seldin MF (1992) *Genomics* **14**, 26-31.

Roth S & Weston J (1967) *Proc. Natl. Acad. Sci USA*, **58**: 974-980.

Sambrook J, Fritsch EF, Maniatis T, (1989) *Molecular Cloning: A Laboratory Manual - 2nd Ed.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

Santos MA (1991) *Nucleic Acids Res.* **19**, 5442.

Schilling *et al.*, (1959) *Surgery*, **46**: 702-710.

Senger DR, Van De Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF (1993) *Cancer Metastasis Rev.* **12**, 303-324.

Sharkey AM, Chamock-Jones DS, Boocock CA, Brown KD, Smith SK, (1993) *J. Reprod. Fertil.* **99**, 609-615.

Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg E, (1993) *J. Leukocyt. Biol.* **55**, 410-422.

Suter U, Angst C, Tien C-L, Drinkwater CC, Lindsay RM and Shooter EM (1992) *J. Neurosci.*, **12**, 306-318.

Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, & Abraham J (1991) *J. Biol. Chem.* **266**, 11947-11954.

Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, Bjorklund A & Gage FH (1986) *Proc. Natl. Acad. Sci. USA* **83**, 9231-9235.

Yan Z, Weich HA, Bernart W, Breckwoldt M, Neulen J, (1993) *J. Clin. Endocrinol. Metab.* **77**, 1723-1725.

Yip NK, Rich KM, Lampe PA & Johnson EM Jr (1984) *J. Neurosci.*, **4**, 2986-2992.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

(countries other than US) AMRAD OPERATIONS PTY. LTD.  
(us only) Hayward, N and Weber, G

## (ii) TITLE OF INVENTION: A NOVEL GROWTH FACTOR AND A GENETIC SEQUENCE ENCODING SAME

## (iii) NUMBER OF SEQUENCES: 14

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: DAVIES COLLISON CAVE  
(B) STREET: 1 LITTLE COLLINS STREET  
(C) CITY: MELBOURNE  
(D) STATE: VICTORIA  
(E) COUNTRY: AUSTRALIA  
(F) ZIP: 3000

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT INTERNATIONAL  
(B) FILING DATE: 22-FEB-1996

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: AU PN1457  
(B) FILING DATE: 02-MAR-1995  
(A) APPLICATION NUMBER: AU PN6647  
(B) FILING DATE: 20-NOV-1995  
(A) APPLICATION NUMBER: AU PN7274  
(B) FILING DATE: 22-DEC-1995

- 37 -

## (viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: HUGHES DR, E JOHN L
- (C) REFERENCE/DOCKET NUMBER: EJH/EK

## (ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: +61 3 9254 2777
- (B) TELEFAX: +61 3 9254 2770

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 649 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 17...589

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TCGGGCCTCC GAAACC ATG AAC TTT CTG CTG TCT TGG GTG CAT TGG AGC	49
Met Asn Phe Leu Leu Ser Trp Val His Trp Ser	
1 5 10	
CTT GCC TTG CTG CTC TAC CTC CAC CAT GCC AAG TGG TCC CAG GCT GCA	97
Leu Ala Leu Leu Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala	
15 20 25	
CCC ATG GCA GAA GGA GGA GGG CAG AAT CAT CAC GAA GTG GTG AAG TTC	145
Pro Met Ala Glu Gly Gly Gln Asn His His Glu Val Val Lys Phe	
30 35 40	
ATG GAT GTC TAT CAG CGC AGC TAC TGC CAT CCA ATC GAG ACC CTG GTG	193
Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val	
45 50 55	
GAC ATC TTC CAG GAG TAC CCT GAT GAG ATC GAG TAC ATC TTC AAG CCA	241
Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro	
60 65 70 75	
TCC TGT GTG CCC CTG ATG CGA TGC GGG GGC TGC TGC AAT GAC GAG GGC	289
Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly	
80 85 90	

- 38 -

CTG GAG TGT GTG CCC ACT GAG GAG TCC AAC ATC ACC ATG CAG ATT ATG	337		
Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met			
95	100	105	
CGG ATC AAA CCT CAC CAA GGC CAG CAC ATA GGA GAG ATG AGC TTC CTA	385		
Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu			
110	115	120	
CAG CAC AAC AAA TGT GAA TGC AGA CCA AAG AAA GAT AGA GCA AGA CAA	433		
Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln			
125	130	135	
GAA AAT CCC TGT GGG CCT TGC TCA GAG CGG AGA AAG CAT TTG TTT GTA	481		
Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val			
140	145	150	155
CAA GAT CCG CAG ACG TGT AAA TGT TCC TGC AAA AAC ACA GAC TCG CGT	529		
Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg			
160	165	170	
TGC AAG GCG AGG CAG CTT GAG TTA AAC GAA CGT ACT TGC AGA TGT GAC	577		
Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp			
175	180	185	
AAG CCG AGG CGG TGAGCCGGGC AGGAGGAAGG AGCCTCCCTC AGCGTTTCGG	629		
Lys Pro Arg Arg			
190			
GAACCAGATC TCTCACCAGG	649		

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 191 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu			
1	5	10	15
Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly			
20	25	30	
Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln			
35	40	45	
Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu			
50	55	60	

- 39 -

Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu  
 65 70 75 80

Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro  
 85 90 95

Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His  
 100 105 110

Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys  
 115 120 125

Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Asn Pro Cys Gly  
 130 135 140

Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr  
 145 150 155 160

Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln  
 165 170 175

Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys Asp Lys Pro Arg Arg  
 180 185 190

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1094 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 3..624

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CC ATG AGC CCT CTG CTC CGC CGC CTG CTG CTC GCC GCA CTC CTG CAG 47  
 Met Ser Pro Leu Leu Arg Arg Leu Leu Ala Ala Leu Leu Gln  
 1 5 10 15

CTG GCC CCC GCC CAG GCC CCT GTC TCC CAG CCT GAT GCC CCT GGC CAC 95  
 Leu Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His  
 20 25 30

CAG AGG AAA GTG GTG TCA TGG ATA GAT GTG TAT ACT CGC GCT ACC TGC 143  
 Gln Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys  
 35 40 45

- 40 -

CAG CCC CGG GAG GTG GTG CCC TTG ACT GTG GAG CTC ATG GGC ACC	191
Gln Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr	
50 55 60	
GTG GCC AAA CAG CTG GTG CCC AGC TGC GTG ACT GTG CAG CGC TGT GGT	239
Val Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly	
65 70 75	
GGC TGC TGC CCT GAC GAT GGC CTG GAG TGT GTG CCC ACT GGG CAG CAC	287
Gly Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His	
80 85 90 95	
CAA GTC CGG ATG CAG ATC CTC ATG ATC CGG TAC CCG AGC AGT CAG CTG	335
Gln Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu	
100 105 110	
GGG GAG ATG TCC CTG GAA GAA CAC AGC CAG TGT GAA TGC AGA CCT AAA	383
Gly Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys	
115 120 125	
AAA AAG GAC AGT GCT GTG AAG CCA GAC AGG GCT GCC ACT CCC CAC CAC	431
Lys Lys Asp Ser Ala Val Lys Pro Asp Arg Ala Ala Thr Pro His His	
130 135 140	
CGT CCC CAG CCC CGT TCT GTT CCG GGC TGG GAC TCT GCC CCC GGA GCA	479
Arg Pro Gln Pro Arg Ser Val Pro Gly Trp Asp Ser Ala Pro Gly Ala	
145 150 155	
CCC TCC CCA GCT GAC ATC ACC CAT CCC ACT CCA GCC CCA GGC CCC TCT	527
Pro Ser Pro Ala Asp Ile Thr His Pro Thr Pro Ala Pro Gly Pro Ser	
160 165 170 175	
GCC CAC GCT GCA CCC AGC ACC ACC AGC GCC CTG ACC CCC GGA CCT GCC	575
Ala His Ala Ala Pro Ser Thr Thr Ser Ala Leu Thr Pro Gly Pro Ala	
180 185 190	
GCT GCC GCT GCC GAC GCA GCT TCC TCC GTT GCC AAG GGC GGG GCT T	624
Ala Ala Ala Ala Asp Ala Ala Ser Ser Val Ala Lys Gly Gly Ala	
195 200 205	
AGAGCTAAC CCAGACACCT GCAGGTGCCG GAAGCTGCGA AGGTGACACA TGGCTTTCA	684
GACTCAGCAG GGTGACTTGC CTCAGAGGCT ATATCCCAGT GGGGAACAA AGGGGAGCCT	744
GGTAAAAAAC AGCCAAGCCC CCAAGACCTC AGCCCAGGCA GAAGCTGCTC TAGGACCTGG	804
GCCTCTCAGA GGGCTTTCT GCCATCCCTT GTCTCCCTGA GGCCATCATC AACACAGGACA	864
GAGTTGGAAG AGGAGACTGG GAGGCAGCAA GAGGGGTAC ATACCAGCTC AGGGGAGAAT	924
GGAGTACTGT CTCAGTTCT AACCACTCTG TGCAAGTAAG CATCTTACAA CTGGCTCTTC	984
CTCCCCTCAC TAAGAAGACC CAAACCTCTG CATAATGGGA TTTGGGCTTT GGTACAAGAA	1044
CTGTGACCCC CAACCCTGAT AAAAGAGATG GAAGGAAAAA AAAAAAAA	1094

- 41 -

## (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 207 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu  
1 5 10 15

Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln  
20 25 30

Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln  
35 40 45

Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val  
50 55 60

Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly  
65 70 75 80

Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln  
85 90 95

Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly  
100 105 110

Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys  
115 120 125

Lys Asp Ser Ala Val Lys Pro Asp Arg Ala Ala Thr Pro His His Arg  
130 135 140

Pro Gln Pro Arg Ser Val Pro Gly Trp Asp Ser Ala Pro Gly Ala Pro  
145 150 155 160

Ser Pro Ala Asp Ile Thr His Pro Thr Pro Ala Pro Gly Pro Ser Ala  
165 170 175

His Ala Ala Pro Ser Thr Thr Ser Ala Leu Thr Pro Gly Pro Ala Ala  
180 185 190

Ala Ala Ala Asp Ala Ala Ser Ser Val Ala Lys Gly Gly Ala  
195 200 205

- 42 -

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 993 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 3..566

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CC ATG AGC CCT CTG CTC CGC CGC CTG CTG CTC GCC GCA CTC CTG CAG	47
Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln	
1 5 10 15	
CTG GCC CCC GCC CAG GCC CCT GTC TCC CAG CCT GAT GCC CCT GGC CAC	95
Leu Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His	
20 25 30	
CAG AGG AAA GTG GTG TCA TGG ATA GAT GTG TAT ACT CGC GCT ACC TGC	143
Gln Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys	
35 40 45	
CAG CCC CGG GAG GTG GTG CCC TTG ACT GTG GAG CTC ATG GGC ACC	191
Gln Pro Arg Glu Val Val Pro Leu Thr Val Glu Leu Met Gly Thr	
50 55 60	
G TG GCC AAA CAG CTG GTG CCC AGC TGC GTG ACT GTG CAG CGC TGT GGT	239
Val Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly	
65 70 75	
GGC TGC TGC CCT GAC GAT GGC CTG GAG TGT GTG CCC ACT GGG CAG CAC	287
Gly Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His	
80 85 90 95	
CAA GTC CGG ATG CAG ATC CTC ATG ATC CGG TAC CCG AGC AGT CAG CTG	335
Gln Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu	
100 105 110	
GGG GAG ATG TCC CTG GAA GAA CAC AGC CAG TGT GAA TGC AGA CCT AAA	383
Gly Glu Met Ser Leu Glu His Ser Gln Cys Glu Cys Arg Pro Lys	
115 120 125	
AAA AAG GAC AGT GCT GTG AAG CCA GAT AGC CCC AGG CCC CTC TGC CCA	431
Lys Lys Asp Ser Ala Val Lys Pro Asp Ser Pro Arg Pro Leu Cys Pro	
130 135 140	

- 43 -

CGC TGC ACC CAG CAC CAC CAG CGC CCT GAC CCC CGG ACC TGC CGC TGC	479
Arg Cys Thr Gln His His Gln Arg Pro Asp Pro Arg Thr Cys Arg Cys	
145 150 155	
CGC TGC CGA CGC CGC AGC TTC CTC CGT TGC CAA GGG CGG GGC TTA GAG	527
Arg Cys Arg Arg Arg Ser Phe Leu Arg Cys Gln Gly Arg Gly Leu Glu	
160 165 170 175	
CTC AAC CCA GAC ACC TGC AGG TGC CGG AAG CTG CGA AGG TGACACATGG	576
Leu Asn Pro Asp Thr Cys Arg Cys Arg Lys Leu Arg Arg	
180 185	
CTTTTCAGAC TCAGCAGGGT GACTTGCTC AGAGGCTATA TCCCAGTGGG GGAACAAAGG	636
GGAGCCTGGT AAAAAACAGC CAAGCCCCA AGACCTCAGC CCAGGCAGAA GCTGCTCTAG	696
GACCTGGGCC TCTCAGAGGG CTCTTCTGCC ATCCCTTGTC TCCCTGAGGC CATCATCAA	756
CAGGACAGAG TTGGAAGAGG AGACTGGGAG GCAGCAAGAG GGGTCACATA CCAGCTCAGG	816
GGAGAATGGA GTACTGTCTC AGTTTCTAAC CACTCTGTGC AAGTAAGCAT CTTACAACTG	876
GCTCTTCCTC CCCTCACTAA GAAGACCCAA ACCTCTGCAT AATGGGATTT GGGCTTTGGT	936
ACAAGAACTG TGACCCCCAA CCCTGATAAA AGAGATGGAA GGAAAAAAA AAAAAAA	993

## (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 188 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu	
1 5 10 15	
Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln	
20 25 30	
Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln	
35 40 45	
Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val	
50 55 60	
Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly	
65 70 75 80	

- 44 -

Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln  
       85                  90                  95  
  
 Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu Gly  
       100              105                  110  
  
 Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys Lys  
       115              120                  125  
  
 Lys Asp Ser Ala Val Lys Pro Asp Ser Pro Arg Pro Leu Cys Pro Arg  
       130              135                  140  
  
 Cys Thr Gln His His Gln Arg Pro Asp Pro Arg Thr Cys Arg Cys Arg  
       145              150                  155                  160  
  
 Cys Arg Arg Arg Ser Phe Leu Arg Cys Gln Gly Arg Gly Leu Glu Leu  
       165              170                  175  
  
 Asn Pro Asp Thr Cys Arg Cys Arg Lys Leu Arg Arg  
       180              185

## (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 858 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 3..431

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CC ATG AGC CCT CTG CTC CGC CGC CTG CTG CTC GCC GCA CTC CTG CAG	47
Met Ser Pro Leu Leu Arg Arg Leu Leu Ala Ala Leu Leu Gln	
1              5                  10                  15	
CTG GCC CCC GCC CAG GCC CCT GTC TCC CAG CCT GAT GCC CCT GGC CAC	95
Leu Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His	
20              25                  30	
CAG AGG AAA GTG GTG TCA TGG ATA GAT GTG TAT ACT CGC GCT ACC TGC	143
Gln Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys	
35              40                  45	
CAG CCC CGG GAG GTG GTG GTG CCC TTG ACT GTG GAG CTC ATG GGC ACC	191
Gln Pro Arg Glu Val Val Pro Leu Thr Val Glu Leu Met Gly Thr	
50              55                  60	

- 45 -

GTG GCC AAA CAG CTG GTG CCC AGC TGC GTG ACT GTG CAG CGC TGT GGT	239
Val Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly	
65 70 75	
GGC TGC TGC CCT GAC GAT GGC CTG GAG TGT GTG CCC ACT GGG CAG CAC	287
Gly Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His	
80 85 90 95	
CAA GTC CGG ATG CAG ATC CTC ATG ATC CGG TAC CCG AGC AGT CAG CTG	335
Gln Val Arg Met Gln Ile Leu Met Ile Arg Tyr Pro Ser Ser Gln Leu	
100 105 110	
GGG GAG ATG TCC CTG GAA GAA CAC AGC CAG TGT GAA TGC AGA CCT AAA	383
Gly Glu Met Ser Leu Glu Glu His Ser Gln Cys Glu Cys Arg Pro Lys	
115 120 125	
AAA AAG GAC AGT GCT GTG AAG CCA GAT AGG TGC CGG AAG CTG CGA AGG	431
Lys Lys Asp Ser Ala Val Lys Pro Asp Arg Cys Arg Lys Leu Arg Arg	
130 135 140	
TGACACATGG CTTTCAGAC TCAGCAGGGT GACTTGCTC AGAGGCTATA TCCCAGTGGG	491
GGAACAAAGG GGAGCCTGGT AAAAAACAGC CAAGCCCCA AGACCTCAGC CCAGGCAGAA	551
GCTGCTCTAG GACCTGGGCC TCTCAGAGGG CTCTTCTGCC ATCCCTTGTC TCCCTGAGGC	611
CATCATAAA CAGGACAGAG TTGGAAGAGG AGACTGGGAG GCAGCAAGAG GGGTCACATA	671
CCAGCTCAGG GGAGAAATGGA GTACTGTCTC AGTTTCTAAC CACTCTGTGC AAGTAAGCAT	731
CTTACAAC TG GCTCTCCTC CCCTCACTAA GAAGACCCAA ACCTCTGCAT AATGGGATT	791
GGGCTTGGT ACAAGAACTG TGACCCCCAA CCCTGATAAA AGAGATGGAA GGAAAAAAA	851
AAAAAAA	858

- 46 -

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 143 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Ser	Pro	Leu	<b>Leu</b>	Arg	Arg	Leu	Leu	Leu	Ala	Ala	Leu	Leu	Gln	Leu
1				5				10						15	
Ala	Pro	Ala	Gln	Ala	Pro	Val	Ser	Gln	Pro	Asp	Ala	Pro	Gly	His	Gln
					20			25					30		
Arg	Lys	Val	Val	<b>Ser</b>	Trp	Ile	Asp	Val	Tyr	Thr	Arg	Ala	Thr	Cys	Gln
				35			40						45		
Pro	Arg	Glu	Val	Val	Val	Pro	Leu	Thr	Val	Glu	Leu	Met	Gly	Thr	Val
					50		55					60			
Ala	Lys	Gln	Leu	Val	Pro	Ser	Cys	Val	Thr	Val	Gln	Arg	Cys	Gly	Gly
				65		70				75			80		
Cys	Cys	Pro	Asp	Asp	Gly	Leu	Glu	Cys	Val	Pro	Thr	Gly	Gln	His	Gln
					85			90					95		
Val	Arg	Met	Gln	Ile	Leu	Met	Ile	Arg	Tyr	Pro	Ser	Ser	Gln	Leu	Gly
				100			105						110		
Glu	Met	Ser	Leu	Glu	Glu	His	Ser	Gln	Cys	Glu	Cys	Arg	Pro	Lys	Lys
				115			120					125			
Lys	Asp	Ser	Ala	Val	Lys	Pro	Asp	Arg	Cys	Arg	Lys	Leu	Arg	Arg	
				130			135					140			

- 47 -

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 910 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 3..305

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CC ATG AGC CCT CTG CTC CGC CGC CTG CTG CTC GCC GCA CTC CTG CAG	47
Met Ser Pro Leu Leu Arg Arg Leu Leu Ala Ala Leu Leu Gln	
1 5 10 15	
CTG GCC CCC GCC CAG GCC CCT GTC TCC CAG CCT GAT GCC CCT GGC CAC	95
Leu Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His	
20 25 30	
CAG AGG AAA GTG GTG TCA TGG ATA GAT GTG TAT ACT CGC GCT ACC TGC	143
Gln Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys	
35 40 45	
CAG CCC CGG GAG GTG GTG CCC TTG ACT GTG GAG CTC ATG GGC ACC	191
Gln Pro Arg Glu Val Val Pro Leu Thr Val Glu Leu Met Gly Thr	
50 55 60	
G TG GCC AAA CAG CTG GTG CCC AGC TGC GTG ACT GTG CAG CGC TGT GGT	239
Val Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly	
65 70 75	
GGC TGC TGC CCT GAC GAT GGC CTG GAG TGT GTG CCC ACT GGG CAG CAC	287
Gly Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His	
80 85 90 95	
CAA GTC CGG ATG CAG ACC TAAAAAAAAG GACAGTGCTG TGAAGCCAGA	335
Gln Val Arg Met Gln Thr	
100	
CAGGGCTGCC ACTCCCCACC ACCGTCCCCA GCCCGTTCT GTTCCGGGCT GGGACTCTGC	395
CCCCGGAGCA CCCTCCCCAG CTGACATCAC CCATCCCACT CCAGCCCCAG GCCCCTCTGC	455
CCACGCTGCA CCCAGCACCA CCAGCGCCCT GACCCCCGGA CCTGCCGCTG CCGCTGCCGA	515
CGCCGCAGCT TCCTCCGTTG CCAAGGGCGG GGCTTAGAGC TCAACCCAGA CACCTGCAGG	575
TGCCGGAAGC TGCAGAAGGTG ACACATGGCT TTTCAGACTC AGCAGGGTGA CTTGCCTCAG	635
AGGCTATATC CCAGTGGGGA ACAAAAGAGGA GCCTGGTAAA AAACAGCCAA GCCCCCCAAGA	695

- 48 -

CCTCAGCCCA GGCAGAAAGCT GCTCTAGGAC CTGGGCCTCT CAGAGGGCTC TTCTGCCATC	755
CCTTGTCTCC CTGAGGCCAT CATCAAACAG GACAGAGTTG GAAGAGGAGA CTGGGAGGCA	815
GCAAGAGGGG TCACATACCA GCTCAGGGGA GAATGGAGTA CTGTCTCAGT TTCTAACAC	875
TCTGTGCAAG TAAGCATCTT ACAACTGGCT CTTCC	910

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 101 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Ser Pro Leu Leu Arg Arg Leu Leu Leu Ala Ala Leu Leu Gln Leu			
1	5	10	15
Ala Pro Ala Gln Ala Pro Val Ser Gln Pro Asp Ala Pro Gly His Gln			
20	25	30	
Arg Lys Val Val Ser Trp Ile Asp Val Tyr Thr Arg Ala Thr Cys Gln			
35	40	45	
Pro Arg Glu Val Val Val Pro Leu Thr Val Glu Leu Met Gly Thr Val			
50	55	60	
Ala Lys Gln Leu Val Pro Ser Cys Val Thr Val Gln Arg Cys Gly Gly			
65	70	75	80
Cys Cys Pro Asp Asp Gly Leu Glu Cys Val Pro Thr Gly Gln His Gln			
85	90	95	
Val Arg Met Gln Thr			
100			

- 49 -

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ACCAACCACCT CCCTGGGCTG GCATGTGGCA CGTGCATAAA CG

42

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AGTTGTTTGA CCACATTGCC CATGAGTTCC ATGCTCAGAG GC

42

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GATCCTGGGG CTGGAGTGGG ATGGATGATG TCAGCTGG

38

- 50 -

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GCAGGGCAGAG GATCCTGGGG CTGTCTGGCC TCACAGCACT

40

## CLAIMS:

1. A biologically isolated proteinaceous molecule having the following characteristics:
  - (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to the sequence set forth in SEQ ID NO:2;
  - (ii) exhibits at least one property in common with vascular endothelial growth factor (VEGF).
2. A proteinaceous molecule according to claim 1 wherein the molecule exhibits at least one of the following properties:
  - (i) an ability to induce vascular endothelial cells;
  - (ii) an ability to interact with *flt-1/flk-1* family of receptors; and/or
  - (iii) an ability to induce cell migration, cell survival and/or an increase in intracellular levels of alkaline phosphatase.
3. A proteinaceous molecule according to claim 1 or 2 wherein said molecule has the capacity to induce astroglial proliferation.
4. A proteinaceous molecule according to claim 1 wherein said molecule is of human origin.
5. A proteinaceous molecule according to claim 1 wherein said molecule is of non-human origin.
6. A proteinaceous molecule according to claim 5 wherein said molecule is of livestock animal, companion animal, laboratory test animal, avian, fish or reptilian origin.
7. A proteinaceous molecule according to claim 5 wherein said molecule is encoded by a gene located at chromosome 11q13.

- 52 -

8. A proteinaceous molecule according to claim 1 wherein the percentage similarity to SEQ ID NO:2 is at least about 30%.

9. A proteinaceous molecule according to claim 1 wherein the percentage similarity to SEQ ID NO:2 is at least about 40%.

10. A proteinaceous molecule according to claim 1 wherein the percentage similarity to SEQ ID NO:2 is at least about 60-70%.

11. A proteinaceous molecule according to claim 1 comprising a sequence of amino acids as set forth in SEQ ID NO:4 or a part, fragment, derivative or analogue thereof.

12. A proteinaceous molecule according to claim 1 comprising an amino acid sequence substantially set forth in SEQ ID NO:6 or a part, fragment, derivative or analogue thereof.

13. A proteinaceous molecule according to claim 1 comprising an amino acid sequence substantially set forth in SEQ ID NO:8 or a part, fragment, derivative or analogue thereof.

14. A proteinaceous molecule according to claim 1 comprising an amino acid sequence substantially set forth in SEQ ID NO:10 or a part, fragment, derivative or analogue thereof.

15. A recombinant molecule having the following characteristics:

- (i) an amino acid sequence substantially as set forth in SEQ ID NO:4 or having at least about 15% similarity to but at least about 5% dissimilarity to the amino acid sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one biological property in common with VEGF.

16. A recombinant molecule having the following characteristics:
  - (i) an amino acid sequence substantially as set forth in SEQ ID NO:6 or having at least about 15% similarity to but at least about 5% dissimilarity to the amino acid sequence set forth in SEQ ID NO:2;
  - (ii) exhibits at least one biological property in common with VEGF.
17. A recombinant molecule having the following characteristics:
  - (i) an amino acid sequence substantially as set forth in SEQ ID NO:8 or having at least about 15% similarity to but at least about 5% dissimilarity to the amino acid sequence set forth in SEQ ID NO:2;
  - (ii) exhibits at least one biological property in common with VEGF.
18. A recombinant molecule having the following characteristics:
  - (i) an amino acid sequence substantially as set forth in SEQ ID NO:10 or having at least about 15% similarity to but at least about 5% dissimilarity to the amino acid sequence set forth in SEQ ID NO:2;
  - (ii) exhibits at least one biological property in common with VEGF.
19. A recombinant molecule according to claim 15 or 16 or 17 or 18 having at least one of the following properties:
  - (a) an ability to induce vascular endothelial cells;
  - (b) an ability to interact with *flt1/flki* family of receptors;
  - (c) an ability to induce cell migration, cell survival and/or increase intracellular levels of alkaline phosphatase.
20. A recombinant molecule according to claim 15 or 16 or 17 or 18 having the capacity to induce astroglial proliferation.

21. A recombinant molecule according to claim 20 wherein the molecule comprises an amino acid sequence substantially as set forth in SEQ ID NO:6.

22. A peptide fragment corresponding to a portion of the amino acid sequence set forth in SEQ ID NO:4 or a derivative or chemical equivalent thereof.

23. A peptide fragment according to claim 22 having the sequence set forth in SEQ ID NO:6 or a chemical equivalent thereof.

24. A peptide fragment according to claim 22 having the sequence set forth in SEQ ID NO:8 or a chemical equivalent thereof.

25. A peptide fragment according to claim 22 having the sequence set forth in SEQ ID NO:10 or a chemical equivalent thereof.

26. A nucleic acid molecule comprising a sequence of nucleotides or complementary to a sequence encoding a proteinaceous molecule having the following characteristics:

- (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to the sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one property in common with vascular endothelial growth factor (VEGF).

27. A nucleic acid molecule according to claim 26 wherein the proteinaceous molecule exhibits at least one of the following properties:

- (i) an ability to induce vascular endothelial cells;
- (ii) an ability to interact with *flt-1/flk-1* family of receptors; and/or
- (iii) an ability to induce cell migration, cell survival and/or an increase in intracellular levels of alkaline phosphatase.

28. A nucleic acid molecule according to claim 27 wherein the proteinaceous molecule has the capacity to induce astroglial proliferation.

29. A nucleic acid molecule according to claim 28 wherein said molecule encodes an amino acid sequence substantially as set forth in SEQ ID NO:6.

30. A nucleic acid molecule according to claim 1 wherein said molecule is of human origin.

31. A nucleic acid molecule according to claim 1 wherein the percentage similarity to SEQ ID NO:2 is at least about 30%.

32. A nucleic acid molecule according to claim 26 comprising a nucleotide sequence substantially as set forth in SEQ ID NO:3 or having at least 15% similarity thereto or capable of hybridising under low stringency conditions to a reverse complement of the nucleotide sequence as set forth in SEQ ID NO:3 provided that the nucleotide sequence has at least 15% similarity but at least 30% dissimilarity to the nucleotide sequence set forth in SEQ ID NO:3.

33. A nucleic acid molecule according to claim 26 encoding a murine homologue of human VEGF and comprising a nucleotide sequence substantially as set forth in Figure 9.

34. A pharmaceutical composition comprising a proteinaceous molecule according to claim 1 or 2 or 3 or 11 and one or more pharmaceutically acceptable carriers and/or diluents.

35. A method for preparing a recombinant molecule having the following characteristics:

- (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to the sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one property in common with vascular endothelial growth factor (VEGF),

said method comprising expressing a nucleic acid molecule encoding said recombinant

molecule by a suitable host grown under conditions effective to synthesise said recombinant molecule and then isolating said molecule.

36. A method according to claim 35 wherein the nucleic acid molecule comprises a sequence of nucleotides as set forth in SEQ ID NO:3 or having at least 15% similarity thereto or is capable of hybridising under low stringency conditions to a reverse complement of the nucleotide sequence as set forth in SEQ ID NO:3 provided that the nucleotide sequence has at least 15% similarity but at least 30% dissimilarity to the nucleotide sequence set forth in SEQ ID NO:3.

37. A method of inducing astroglial proliferation in a mammal, said method comprising administering to said mammal an effective amount of a recombinant proteinaceous molecule having the characteristics:

- (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to the sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one property in common with vascular endothelial growth factor (VEGF),

said administration being for a time and under conditions sufficient to induce astroglial proliferation.

38. A method according to claim 37 wherein the recombinant proteinaceous molecule comprises an amino acid sequence substantially as set forth in SEQ ID NO:3 or is a derivative thereof.

39. A method according to claim 37 wherein the recombinant proteinaceous molecule comprises an amino acid sequence substantially as set forth in SEQ ID NO:6 or is a derivative thereof.

40. A method of promoting neuronal survival and/or proliferation in a mammal, said method comprising administering to said mammal an effective amount of a recombinant proteinaceous molecule having the characteristics:

- 57 -

- (i) comprises an amino acid sequence having at least about 15% similarity but at least about 5% dissimilarity to the sequence set forth in SEQ ID NO:2;
- (ii) exhibits at least one property in common with vascular endothelial growth factor (VEGF),

said administration being for a time and under conditions sufficient to induce astroglial proliferation.

41. A method according to claim 40 wherein the recombinant proteinaceous molecule comprises an amino acid sequence substantially as set forth in SEQ ID NO:3 or is a derivative thereof.

41. A method according to claim 40 wherein the recombinant proteinaceous molecule comprises an amino acid sequence substantially as set forth in SEQ ID NO:6 or is a derivative thereof.

## ABSTRACT

The present invention relates generally to an isolated molecule having vascular endothelial growth factor-like properties and to a genetic sequence encoding same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of conditions requiring enhanced or diminished vasculature and/or vascular permeability. The molecule of the present invention is also a useful effector of primary and central neurons and is capable of inducing astroglial proliferation.

APPROVED BY	O.G. FIG. CLASS SUBCLASS
DRAFTSMAN	

08/765588  
PCT/AU96/0004

1/52

2/52	3/52
<i>Fig.1(i)</i>	<i>Fig.1(ii)</i>
4/52	5/52
<i>Fig.1(iii)</i>	<i>Fig.1(iv)</i>

2/52

Fig. 1(i)

APPROVED BY	O.G. FIG. CLASS & SUBCLASS
DRAFTSMAN	

08/765588  
PCT/AU96/00094

3/52

CTG TCT TGG GTG CAT TGG AGC	49
Leu Ser Trp Val His Trp Ser	
5	10
CAT GCC AAG TGG TCC CAG GCT GCA	97
His Ala Lys Trp Ser Gln Ala Ala	
20	25
AAT CAT CAC GAA GTG GTG AAG TTC	145
Asn His His Glu Val Val Lys Phe	
40	
TGC CAT CCA ATC GAG ACC CTG GTG	193
Cys His Pro Ile Glu Thr Leu Val	
55	
GAG ATC GAG TAC ATC TTC AAG CCA	241
Glu Ile Glu Tyr Ile Phe Lys Pro	
70	75
GGG GGC TGC TGC AAT GAC GAG GGC	289
Gly Gly Cys Cys Asn Asp Glu Gly	
85	90
TCC AAC ATC ACC ATG CAG ATT ATG	337
Ser Asn Ile Thr Met Gln Ile Met	
100	105
CAC ATA GGA GAG ATG AGC TTC CTA	385
His Ile Gly Glu Met Ser Phe Leu	
120	

Fig.1(ii)

APPROVED BY	O.G. FIG. CLASS
DRAFTSMAN	CLASS

08/765588  
PCO/AU96/00094

4/52

386	CAG	CAC	AAC	AAA	TGT	GAA	TGC	AGA
	Gln	His	Asn	Lys	Cys	Glu	Cys	Arg
	125						130	
434	GAA	AAT	CCC	TGT	GGG	CCT	TGC	TCA
	Glu	Asn	Pro	Cys	Gly	Pro	Cys	Ser
	140					145		
482	CAA	GAT	CCG	CAG	ACG	TGT	AAA	TGT
	Gln	Asp	Pro	Gln	Thr	Cys	Lys	Cys
					160			
530	TGC	AAG	GCG	AGG	CAG	CTT	GAG	TTA
	Cys	Lys	Ala	Arg	Gln	Leu	Glu	Leu
				175				
578	AAG	CCG	AGG	CGG	TGAGCCGGGC AGGAG			
	Lys	Pro	Arg	Arg				
			190					
630	GAACCAGATC TCTCACCAAGG							

Fig.1(iii)

APPROVED BY	O.G. FIG.
DRAFTSMAN	CLASS SUBCLASS W698/2700

08/765588  
Q/AU9600094

5/52

CCA AAG AAA GAT AGA GCA AGA CAA 433  
Pro Lys Lys Asp Arg Ala Arg Gln  
135

GAG CGG AGA AAG CAT TTG TTT GTA 481  
Glu Arg Arg Lys His Leu Phe Val  
150 155

TCC TGC AAA AAC ACA GAC TCG CGT 529  
Ser Cys Lys Asn Thr Asp Ser Arg  
165 170

AAC GAA CGT ACT TGC AGA TGT GAC 577  
Asn Glu Arg Thr Cys Arg Cys Asp  
180 185

GAAGG AGCCTCCCTC AGCGTTTCGG 629

649

Fig.1(iv)

APPROVED BY	QC FIG 0007
DRAFTSMAN	CLASS SUBCLASS

08/765588  
PCT/AU96/00094

6/52

7/52	8/52
<i>Fig. 2(i)</i>	<i>Fig. 2(ii)</i>
9/52	10/52
<i>Fig 2(iii)</i>	<i>Fig 2(iv)</i>
11/52	12/52
<i>Fig 2(v)</i>	<i>Fig 2(vi)</i>

APPROVED BY	08/06/96 PCPAU96/00094
DRAFTSMAN	CLASS SUBCLASS

08/765588

7/52

1	CC ATG AGC CCT CTG CTC CGC CGC Met Ser Pro Leu Leu Arg Arg 1 5
48	CTG GCC CCC GCC CAG GCC CCT GTC Leu Ala Pro Ala Gln Ala Pro Val 20
96	CAG AGG AAA GTG GTG TCA TGG ATA Gln Arg Lys Val Val Ser Trp Ile 35
144	CAG CCC CGG GAG GTG GTG GTG CCC Gln Pro Arg Glu Val Val Val Pro 50 55
192	GTG GCC AAA CAG CTG GTG CCC AGC Val Ala Lys Gln Leu Val Pro Ser 65 70
240	GGC TGC TGC CCT GAC GAT GGC CTG Gly Cys Cys Pro Asp Asp Gly Leu 80 85
288	CAA GTC CGG ATG CAG ATC CTC ATG Gln Val Arg Met Gln Ile Leu Met 100
336	GGG GAG ATG TCC CTG GAA GAA CAC Gly Glu Met Ser Leu Glu Glu His 115

Fig.2(i)

APPROVED BY	CLASS	FIG NO 7007 SUBCLASS
DRAFTSMAN		

08765588  
PCT/AU96/00094

8/52

CTG	CTG	CTC	GCC	GCA	CTC	CTG	CAG		47
Leu	Leu	Leu	Ala	Ala	Leu	Leu	Gln		
		10					15		
TCC	CAG	CCT	GAT	GCC	CCT	GGC	CAC		95
Ser	Gln	Pro	Asp	Ala	Pro	Gly	His		
	25					30			
GAT	GTG	TAT	ACT	CGC	GCT	ACC	TGC		143
Asp	Val	Tyr	Thr	Arg	Ala	Thr	Cys		
	40				45				
TTG	ACT	GTG	GAG	CTC	ATG	GGC	ACC		191
Leu	Thr	Val	Glu	Leu	Met	Gly	Thr		
		60							
TGC	GTG	ACT	GTG	CAG	CGC	TGT	GGT		239
Cys	Val	Thr	Val	Gln	Arg	Cys	Gly		
		75							
GAG	TGT	GTG	CCC	ACT	GGG	CAG	CAC		287
Glu	Cys	Val	Pro	Thr	Gly	Gln	His		
		90				95			
ATC	CGG	TAC	CCG	AGC	AGT	CAG	CTG		335
Ile	Arg	Tyr	Pro	Ser	Ser	Gln	Leu		
		105				110			
AGC	CAG	TGT	GAA	TGC	AGA	CCT	AAA		383
Ser	Gln	Cys	Glu	Cys	Arg	Pro	Lys		
	120				125				

Fig.2(ii)

APPROVED BY DRAFTSMAN	O.G. FIG. CLASS 61007 ASS
-----------------------------	------------------------------

081765588  
ACTAUG/00094

9/52

384	AAA	AAG	GAC	AGT	GCT	GTG	AAG	CCA
	Lys	Lys	Asp	Ser	Ala	Val	Lys	Pro
			130					135
432	CGT	CCC	CAG	CCC	CGT	TCT	GTT	CCG
	Arg	Pro	Gln	Pro	Arg	Ser	Val	Pro
		145					150	
480	CCC	TCC	CCA	GCT	GAC	ATC	ACC	CAT
	Pro	Ser	Pro	Ala	Asp	Ile	Thr	His
		160				165		
528	GCC	CAC	GCT	GCA	CCC	AGC	ACC	ACC
	Ala	His	Ala	Ala	Pro	Ser	Thr	Thr
					180			
576	GCT	GCC	GCT	GCC	GAC	GCC	GCA	GCT
	Ala	Ala	Ala	Ala	Asp	Ala	Ala	Ala
				195				

Fig. 2(iii)

APPROVED BY	O.G. FIG. CLASS 1000 SUBCLASS 7
DRAFTSMAN	

08/765588  
PCT/AU96/00094

10/52

GAC	AGG	GCT	GCC	ACT	CCC	CAC	CAC	431	
Asp	Arg	Ala	Ala	Thr	Pro	His	His		
140									
GGC	TGG	GAC	TCT	GCC	CCC	GGA	GCA	479	
Gly	Trp	Asp	Ser	Ala	Pro	Gly	Ala		
155									
CCC	ACT	CCA	GCC	CCA	GGC	CCC	TCT	527	
Pro	Thr	Pro	Ala	Pro	Gly	Pro	Ser		
170								175	
AGC	GCC	CTG	ACC	CCC	GGA	CCT	GCC	575	
Ser	Ala	Leu	Thr	Pro	Gly	Pro	Ala		
185								190	
TCC	TCC	GTT	GCC	AAG	GGC	GGG	GCT	T	624
Ser	Ser	Val	Ala	Lys	Gly	Gly	Gly	Ala	
200								205	

Fig.2(iv)

APPROVED	O. G. FIG. W-1002485
BY	CLASS SUBCLASS
DRAFTSMAN	

08765588  
RCAU96/0094

11/52

625	AGAGCTCAAC	CCAGACACCT	GCAGGTGCCG
685	GAATCAGCAG	GGTGACTTGC	CTCAGAGGCT
745	GGTAAAAAAC	AGCCAAGCCC	CCAAGACCTC
805	GCCTCTCAGA	GGGCTCTTCT	GCCATCCCTT
865	GAGTTGGAAG	AGGAGACTGG	GAGGCAGCAA
825	GGAGTACTGT	CTCAGTTCT	AACCACTCTG
985	CTCCCCTCAC	TAAGAAGACC	CAAACCTCTG
1045	CTGTGACCCCC	CAACCCTGAT	AAAAGAGATG

Fig. 2(v)

APPROVED BY DRAFTSMAN	O.G. FIG. CLASS / SUBCLASS
-----------------------------	-------------------------------

08/765588  
PCT/AT96/00094

12/52


GAAGCTGCGA	AGGTGACACA	TGGCTTTCA	684
ATATCCCAGT	GGGGGAACAA	AGGGGAGCCT	744
AGCCCAGGCA	GAAGCTGCTC	TAGGACCTGG	804
GTCTCCCTGA	GGCCATCATC	AAACAGGACA	864
GAGGGGTCAC	ATACCAGCTC	AGGGGAGAAT	924
TGCAAGTAAG	CATCTTACAA	CTGGCTCTTC	984
CATAATGGGA	TTTGGGCTTT	GGTACAAGAA	1044
GAAGGAAAAAA	AAAAAAAAAAA		1094

*Fig.2(vi)*

APPROVED	O.G. FIG.
BY	CLASS 56 2980
DRAFTSMAN	

08/765588  
107/AU9600094

13/52



APPROVED	Q656
BY	0007
DRAFTSMAN	CLASS SUBCLASS

086765588  
07/06/04

14/52

>VEGF\_HUMAN VEGF\_HUMAN VASCULAR ENDOTHELIAL  
(VASCULAR 215 AA.  
LENGTH = 215

SCORE = 181 (92.4 BITS), EXPECT = 6.4e-20,  
IDENTITIES = 33/75 (44%), POSITIVES = 48/75

QUERY: 31 HQRKVVSVIDVYTRATCQPREVVPLTVEL  
+++ VV +DVY R+ C+P E +V + E

SBJCT: 36 NHHEVVVKFMDVYQRSYCHPIETLVDIFQEY

QUERY: 91 PTGQHQVCRMQILMIR 105  
PT + + MQI+ I+

SBJCT: 96 PTEESNITMQIMRIK 110

SCORE = 76 (38.8 BITS), EXPECT = 0.0011,  
IDENTITIES = 12/19 (63%), POSITIVES = 16/19

QUERY: 110 QLGEMSLEEHSQCECRPKK 128  
++GEMS +H+ CECRPKK

SBJCT: 116 HIGEMSFLQHNKCECRPKK 134

SCORE = 72 (36.8 BITS), EXPECT = 0.0046,  
IDENTITIES = 14/21 (66%), POSITIVES = 15/21

QUERY: 202 RCQGRGLELNPDTCRCKLRR 222  
RC +R LEQN TCRC K RR

SBJCT: 195 RCKARQLELNERTCRCDKPRR 215

SCORE = 46 (23.5 BITS), EXPECT = 47.,  
IDENTITIES = 6/10 (60%), POSITIVES = 9/10

QUERY: 187 DPRTCRCKR 196  
DP+TC+C C+

SBJCT: 181 DPQTCKCSCK 190  
SUBSTITUTE SHEET (RULE 26)

Fig.3(i)

APPROVED BY	O.G. FIG. APR 2007
DRAFTSMAN	CLASS SUBCLASS

08/765588  
PCTAU96/00094

15/52

GROWTH FACTOR PRECURSOR (VEGF)

$P = 6.4e-20$   
(64%)

MGTVAKQLVPSCVTVQRCGGCCPDDGLECV 90  
+ PSCV + RCGGCC D+GLECV  
PDEIEYIFKPSCVPLMRCGGCCNDEGLECV 95

POISSON  $P(2) = 9.1e-12$   
(84%)

POISSON  $P(3) = 3.6e-18$   
(71%)

POISSON  $P(4) = 7.3e-10$   
(90%)

*Fig. 3(i)*

APPROVED BY	Q.G. FIG. WAS/97/0007	CLASS	SUBCLASS
DRAFTSMAN			

08/765588  
PCU/096/00094

16/52

17/52	18/52
<i>Fig. 4(i)</i>	<i>Fig. 4(ii)</i>
19/52	20/52
<i>Fig. 4(iii)</i>	<i>Fig. 4(iv)</i>

APPROVED	O.G. FIG.
BY	CLASS / SUBCLASS
DRAFTSMAN	

08/765588  
PCP/AU96/00094

17/52

Gap Weight:3.00 Average Match:1.000  
Length Weight:0.100 Average Mismatch:-0.900  
Quality:100.9 Length:739  
Ratio:0.175 Gaps:30  
Percent Percent  
Similarity:69.703 Identity:69.703

28	ATGAGCCCTCTGCTCCGCCGCCCTGC 
17	ATGAACTTTCTGCT.....GTCT...
68	TGCAGCTGGCCCCGCCAGGCC 
57	TGCTGCTCTACCTCCACCATGCCAA
.18	CACCAGAGGA..... 
.06	AGAAGGAGGAGGGCAGAATCATCAC
40	GTGTATACTCGC . GCTACCTGCCAG 
52	GTCTATCAGCGCAGCTA . CTGCCAT
94	T . . . . GA . . . . CTGTGGAGCTCAT 
01	TCCAGGAGTACCCCTGATGAGATCGA
35	CCCAGCTGCGTGACTGTGCAGCGCT 
39	CCATCCTGTGTGCCCTGATGCGAT
85	CCTGGAGTGTGTGCCCACTGGGCAG 
89	CCTGGAGTGTGTGCCCACTGAGGAG

Fig. 4(i)

APPROVED BY	O.G. FIG.
DRAFTSMAN	CLASS 582700 SUBCLASS

02/765588  
PCTAU96/00094

18/52

TGCTCGCCGCACT.....CC	67
...TGGGTGCATTGGAGCCTTGCCT	56
TGTCTCCCAGCCTGATGCCCTGGC	117
GTGGTCCCAGGCTGCA.CCCATGGC	105
.AAGTGGTG....TCATGGATAGAT	147
GAAGTGGTGAAGTTCATG....GAT	151
CCCCGGGAG...GTGGTGGTGCCCT	193
CCAATCGAGACCCTGGTGGACATCT	200
GGGCACCGTGGCAAACAGCTGGTG	234
GTACATCTT...CAA.....G	238
GTGGTGGCTGCTGCCCTGACGATGG	284
GCGGGGGCTGCTGCAATGACGAGGG	288
CACCAAGTCCGGATGCAGAT.....	329
TCCAACATCACCATGCAGATTATGC	338

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	W 0 9 6 2 7 0 0 7

08/765588  
PCT/EP/60009

19/52

330	.....CCTCATGATCCGGTACC
339	GGATCAAACCTCA.....C
369	GTCCCTGGAAGAACACAGCCAGTGT
376	GAGCTTCCTACAGCACAAACAAATGT
419	GTGCTGTGAAGCCAGACAGGGCTGC
423	G.....AGCAAGACAAG.....
469	CGTTCTGTTCCGGGCTGGGACTCTG
443	...TGTGGGCCTTGCTCAGA.....
519	CATCACCCATCCCACTCCAGCCCCA
468	.....
569	GC.....ACCACCAAGCGCCC
469	GCATTGTTGTACAA.....
609	TGCCGACGCCGCAGCTTCCTCCGTT
509	TG.CAAAAAACACAGACTC..GCGTT
657	AACCCAGACACCTGCAGGTGCCGGA
554	AACGAACGTACTTGCAGATGTGACA

Fig.4(iii)

APPROVED BY DRAFTSMAN	O.G. FIG. CLASS
-----------------------------	--------------------

08/765588  
PCTAU96/00094

20/52

CGAGCAGTCAGC . . . TGGGGGAGAT	368
CAAG . . GCCAGCACATAGGAGAGAT	375
GAATGCAGACCTAAAAAAAGGACA	418
GAATGCAGACC . . . AAAGAAAGATA	422
CACTCCCCACCACCGTCCCCAGCCC	468
. . . . . AAAATCCC . . . . .	442
CCCCCGGAGCACCCTCCCCAGCTGA	518
. . . GCGGAGAA . . . . . . . . .	467
GGCCCCTCTGCCAACGCTGCACCCA	568
. . . . . . . . . A	468
TGACCCCCGGACCTGCCGCTGCCGC	608
. GATCCCGAGACGTGTAAATGTTCC	508
GCCAAGGGCGGGGC . . TTAGAGCTC	656
GC . . AAGGCGAGGCAGCTTGAGTTA	553
AGCTGCGAAGGTGA	695
AGCCGAGGCAGGTGA	592

Fig.4(iv)

APPROVED BY DRAFTSMAN	O.G. FIG. CLASS / SUBCLASS
-----------------------------	-------------------------------

08/765588  
PCPAU96/00094

21/52

22/52	23/52	24/52
<i>Fig.5(i)</i>	<i>Fig.5(ii)</i>	<i>Fig.5(iii)</i>
25/52	26/52	27/52
<i>Fig.5(iv)</i>	<i>Fig.5(v)</i>	<i>Fig.5(vi)</i>

APPROVED BY DRAFTSMAN	O.G. FIG. CLASS W0961700	1 SUBCLASS 8
-----------------------------	--------------------------------	--------------------

08/765588  
TQ/AU9600094

22/52

165SOMSQ.MSF.msf MSF:687

Type: D Tuesday, June 20, 1995

Check:3140

1

VEGF165	ATGAACCTTCTGCTGTCTTGGGTG
SOM175	ATGAGCCCTCTGCTCCGCCGCCTG
SOM175-e6	ATGAGCCCTCTGCTCCGCCGCCTG
SOM175-e6&7	ATGAGCCCTCTGCTCCGCCGCCTG
SOM175-e4	ATGAGCCCTCTGCTCCGCCGCCTG

81

VEGF165	CACCCATGGCAGAAGGAGGGAGGGC
SOM175	TGCCCCTGGCCACCAGAGGAAAGT
SOM175-e6	TGCCCCTGGCCACCAGAGGAAAGT
SOM175-e6&7	TGCCCCTGGCCACCAGAGGAAAGT
SOM175-e4	TGCCCCTGGCCACCAGAGGAAAGT

161

VEGF165	CCAATCGAGACCCTGGTGGACATC
SOM175	GTGGTGGTGCCCTTGACTG.TGGA
SOM175-e6	GTGGTGGTGCCCTTGACTG.TGGA
SOM175-e6&7	GTGGTGGTGCCCTTGACTG.TGGA
SOM175-e4	GTGGTGGTGCCCTTGACTG.TGGA

241

VEGF165	GATGCGATGCGGGGCTGCTGCAA
SOM175	GCAGCGCTGTGGTGGCTGCTGCC
SOM175-e6	GCAGCGCTGTGGTGGCTGCTGCC
SOM175-e6&7	GCAGCGCTGTGGTGGCTGCTGCC
SOM175-e4	GCAGCGCTGTGGTGGCTGCTGCC

Fig.5(i)

APPROVED BY DRAFTSMAN	O.G. FIG. CL 100 SUBD BASS
-----------------------------	-------------------------------

084765588  
PCTAU 96/00094

23/52

CATTGGAGCCTTGCCTGCTGCTCTACC  
CTGCTCGCCGCACTCCTGCAGCTGGCCC  
CTGCTCGCCGCACTCCTGCAGCTGGCCC  
CTGCTCGCCGCACTCCTGCAGCTGGCCC  
CTGCTCGCCGCACTCCTGCAGCTGGCCC

AGAATCATCACGAAGTGGTGAAGTTCAT  
GGTGTCATGGATAGATGTGTATACTCGC  
GGTGTCATGGATAGATGTGTATACTCGC  
GGTGTCATGGATAGATGTGTATACTCGC  
GGTGTCATGGATAGATGTGTATACTCGC

TTCCAGGAGTACCCCTGATGAGATCGAGT  
GCTCATGGCACCGTGGCCAAAC..AGC  
GCTCATGGCACCGTGGCCAAAC..AGC  
GCTCATGGCACCGTGGCCAAAC..AGC  
GCTCATGGCACCGTGGCCAAAC..AGC

TGACGAGGGCCTGGAGTGTGTGCCCACT  
TGACGATGGCCTGGAGTGTGTGCCCACT  
TGACGATGGCCTGGAGTGTGTGCCCACT  
TGACGATGGCCTGGAGTGTGTGCCCACT  
TGACGATGGCCTGGAGTGTGTGCCCACT

*Fig. 5(ii)*

APPROVED BY DRAFTSMAN	O.G. FIG. CLASS 56 SUB CLASS
-----------------------------	---------------------------------

08/765588  
CTA U96/1004

24/52

80

TCCACCATGCCAAGTGGTCCCAGGCTG.  
CCGCCCAGGCCCCTGTCTCCCAGCCTGA  
CCGCCCAGGCCCCTGTCTCCCAGCCTGA  
CCGCCCAGGCCCCTGTCTCCCAGCCTGA  
CCGCCCAGGCCCCTGTCTCCCAGCCTGA

160

GGATGTCTATCAGCGCAGCTACTGCCAT  
G.....CTACCTGC.CAGCC.CCGGGAG  
G.....CTACCTGC.CAGCC.CCGGGAG  
G.....CTACCTGC.CAGCC.CCGGGAG  
G.....CTACCTGC.CAGCC.CCGGGAG

240

ACATTTCAAGCCATCCTGTGTGCCCT  
TGGTGCCCAG.....CTGCGTGACTGT  
TGGTGCCCAG.....CTGCGTGACTGT  
TGGTGCCCAG.....CTGCGTGACTGT  
TGGTGCCCAG.....CTGCGTGACTGT

320

GAGGAGTCCAACATCACCATGCAGATTA  
GGGCAGCACCAAGTCCGGATGCAGATCC  
GGGCAGCACCAAGTCCGGATGCAGATCC  
GGGCAGCACCAAGTCCGGATGCAGATCC  
GGGCAGCACCAAGTCCGGATGCAGA...

Fig.5(iii)

25/52

	321
VEGF165	TGC GGATCAAACCTCACCAAGGCC
SOM175	TCATGATCCGG...TACCCGAGCA
SOM175-e6	TCATGATCCGG...TACCCGAGCA
SOM175-e6&7	TCATGATCCGG...TACCCGAGCA
SOM175-e4	.....
	401
VEGF165	AAGAAAAGATAG.....AGCAA
SOM175	AAAAAAGGACAGTGCTGTGAAGCCA
SOM175-e6	AAAAAAGGACAGTGCTGTGAAGCCA
SOM175-e6&7	AAAAAAGGACAGTGCTGTGAAGCCA
SOM175-e4	AAAAAAGGACAGTGCTGTGAAGCCA
	481
VEGF165	.....AAGCA.....
SOM175	CTCTGCCCGGGAGCACCCCTCCCC
SOM175-e6	.....
SOM175-e6&7	.....
SOM175-e4	CTCTGCCCGGGAGCACCCCTCCCC
	561
VEGF165	A.....GATCCGCA
SOM175	GCACCACCAGCGCCCTGACCCCCG
SOM175-E6	GCACCACCAGCGCCCTGACCCCCG
SOM175-e6&7	.....
SOM175-e4	GCACCACCAGCGCCCTGACCCCCG
	641
VEGF165	TTGAGTTAACGAAACGTACTTGCA
SOM175	TAGAGCTCAACCCAGACACCTGCA
SOM175-e6	TAGAGCTCAACCCAGACACCTGCA
SOM175-e6&7	.....
SOM175-e4	TAGAGCTCAACCCAGACACCTGCA

Fig.5(iv)

APPROVED BY DRAFTSMAN	O.G. FIG. CLASS 962700 SURGLASS
-----------------------------	------------------------------------

08/765588  
PCT/AU96/00094

26/52

AGCACATAGGAGAGATGAGCTTCCTACA  
GTCAGCTGGGGGAGATGTCCCTGGAAAGA  
GTCAGCTGGGGGAGATGTCCCTGGAAAGA  
GTCAGCTGGGGGAGATGTCCCTGGAAAGA  
.....

GACAAGAA.....AATCCCTGTGG.....  
GACAGGGCTGCCACTCCCCACCACCGTC  
GATAG.....  
GATAG.....  
GACAGGGCTGCCACTCCCCACCACCGTC

.....  
AGCTGACATCACCCATCCCACTCCAGCC  
.....CC  
.....  
AGCTGACATCACCCATCCCACTCCAGCC

GACGTGTAAATGTTCTGCAAAAAC.AC  
GACCTGCCGCTGCCGCTGCCGACGCCGC  
GACCTGCCGCTGCCGCTGCCGACGCCGC  
.....  
GACCTGCCGCTGCCGCTGCCGACGCCGC

687

GATGTGACAAGCCGAGGCAGGTGA  
GGTGCAGGAAGCTGCGAAGGTGA  
GGTGCAGGAAGCTGCGAAGGTGA  
. GTGCCGGAAGCTGCGAAGGTGA  
GGTGCAGGAAGCTGCGAAGGTGA

Fig.5(v)

APPROVED BY	O.G. FIG.
DRAFTSMAN	CLASS SUBCLASS WOS 90 2700

08/765588  
PCT/AU90/00094

27/52

400

GCACAAACAAATGTGAATGCAGACC...A  
ACACAGCCAGTGTGAATGCAGACCTAAA  
ACACAGCCAGTGTGAATGCAGACCTAAA  
ACACAGCCAGTGTGAATGCAGACCTAAA  
.....CCTAAA

480

.....GCCTTGCTCAGAGCGGGAGA  
CCCAGCCCCGTTCTGTTCCGGGCTGGGA  
.....  
.....  
CCCAGCCCCGTTCTGTTCCGGGCTGGGA

560

.....TTTGTT.....TGTAC..A  
CCAGGGCCCTCTGCCAACGCTGCACCCA  
CCAGGGCCCTCTGCCAACGCTGCACCCA  
.....  
CCAGGGCCCTCTGCCAACGCTGCACCCA

640


AGACTCG..CGTTGCAAGGCGAGGCAGC  
AGCTTCCTCCGTTGCCAAGGGCGGGGCT  
AGCTTCCTCCGTTGCCAAGGGCGGGGCT  
.....  
AGCTTCCTCCGTTGCCAAGGGCGGGGCT

Fig.5(vi)

APPROVED	O.G. FIG.
BY	CLASSE 6200 ASS
DRAFTSMAN	

08/76588  
PCT/AU96/00094

28/52



APPROVED BY	O.G. FIG.
DRAFTSMAN	CLASS SUBCLASS W096/27007

08/765588  
PCT/AU96/00094

29/52

VEGF <sub>165</sub> SOM175 <sub>Short</sub>	M N F <span style="border: 1px solid black; padding: 2px;">L L</span> S W V H W S <span style="border: 1px solid black; padding: 2px;">L A</span> L L Y <span style="border: 1px solid black; padding: 2px;">L H</span> H A K W S Q A A P M S P <span style="border: 1px solid black; padding: 2px;">L L</span> R R L L . . L A A L Q <span style="border: 1px solid black; padding: 2px;">L L</span> A P A Q . . . A P
VEGF <sub>165</sub> SOM175 <sub>Short</sub>	I F Q <span style="border: 1px solid black; padding: 2px;">E Y</span> P D E I E Y I F K P S C V P L M R C G G C C N L T V <span style="border: 1px solid black; padding: 2px;">E L</span> M G T V A K Q L V P S C V T V Q R C G G C C P
VEGF <sub>165</sub> SOM175 <sub>Short</sub>	F L Q <span style="border: 1px solid black; padding: 2px;">H N K</span> C E C R P K K . . . . D R A . . . . L E E H S Q C E C R P K K K D S A V K P D R A A T P H H
VEGF <sub>165</sub> SOM175 <sub>Short</sub>	C K C S C K N T D S R C K A R Q L E L N E R T C R C D K H A A P S T T S A L T P G P A A A A D A A S S V A K
OR . . .	
VEGF <sub>165</sub> SOM175 <sub>Long</sub>	M N F <span style="border: 1px solid black; padding: 2px;">L L</span> S W V H W S <span style="border: 1px solid black; padding: 2px;">L A</span> L L Y <span style="border: 1px solid black; padding: 2px;">L H</span> H A K W S Q A A P M S P <span style="border: 1px solid black; padding: 2px;">L L</span> R R L L . . L A A L Q <span style="border: 1px solid black; padding: 2px;">L L</span> A P A Q . . . A P
VEGF <sub>165</sub> SOM175 <sub>Long</sub>	I F Q <span style="border: 1px solid black; padding: 2px;">E Y</span> P D E I E Y I F K P S C V P L M R C G G C C N L T V <span style="border: 1px solid black; padding: 2px;">E L</span> M G T V A K Q L V P S C V T V Q R C G G C C P
VEGF <sub>165</sub> SOM175 <sub>Long</sub>	F L Q <span style="border: 1px solid black; padding: 2px;">H N K</span> C E C R P K K . . . . D R A . . . . L E E H S Q C E C R P K K K D S A V K P D R A A T P H H
VEGF <sub>165</sub> SOM175 <sub>Long</sub>	G P <span style="border: 1px solid black; padding: 2px;">C</span> S E R R K H L F V Q D P Q <span style="border: 1px solid black; padding: 2px;">T C</span> K C S C K N T D S P R <span style="border: 1px solid black; padding: 2px;">C</span> T Q H H Q R . . . P D P R <span style="border: 1px solid black; padding: 2px;">T C</span> R C R C R R R S F L

Fig.6(ii)

APPROVED	O.G. FIG.
BY	SEARCHED
DRAFTSMAN	CLASS

08/765588  
PCT/AU96/00094

M	A	E	G	G	G	Q	N	H	H	E	·	V	V	K	F	M	D	V	Y	Q	R	S	Y	C	H	P	I	E	T	L	V	D	60	
V	S	Q	P	D	A	P	G	H	Q	R	K	·	V	V	S	W	I	D	V	Y	T	R	A	T	C	C	P	R	E	V	V	V	P	55
D	E	G	L	E	C	V	P	T	E	E	S	N	I	T	M	Q	I	M	R	I	K	P	H	Q	Q	Q	H	I	G	E	M	S	121	
D	D	G	L	E	C	V	P	T	G	Q	H	Q	V	R	M	Q	I	L	M	I	R	·	Y	P	S	S	Q	L	G	E	M	S	115	

·	·	·	·	·	·	·	·	·	R	Q	E	N	P	C	G	P	C	S	E	R	R	K	H	L	F	·	V	Q	D	P	Q	T	170	
R	P	Q	P	R	S	V	P	G	W	D	S	A	P	P	G	A	P	S	P	A	D	I	T	H	P	T	P	A	P	G	P	S	A	175
P	R	R	G	G	A																													

30/52  
207

M	A	E	G	G	G	Q	N	H	H	E	·	V	V	K	F	M	D	V	Y	Q	R	S	Y	C	H	P	I	E	T	L	V	D	60	
V	S	Q	P	D	A	P	G	H	Q	R	K	·	V	V	S	W	I	D	V	Y	T	R	A	T	C	Q	P	R	E	V	V	V	P	55
D	E	G	L	E	C	V	P	T	E	E	S	N	I	T	M	Q	I	M	R	I	K	P	H	Q	Q	H	I	G	E	M	S	121		
D	D	G	L	E	C	V	P	T	G	Q	H	Q	V	R	M	Q	I	L	M	I	R	·	Y	P	S	S	Q	L	G	E	M	S	115	
R	Q	E	N	P	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·		
R	P	Q	R	S	V	P	G	W	D	S	A	P	G	A	P	S	P	A	D	I	T	H	P	T	P	A	P	G	P	L	C	170		
R	C	K	A	R	Q	L	E	L	N	E	R	T	C	R	C	D	K	P	R	R	R	R	R	R	R	R	R	R	R	R	R	C	177	

191  
222

Fig. 6 (iii)

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	WO 9627007

08/76588  
PCT/AU96/00094

31/52

Areas of 100% homology are boxed and conserved residues thought to be involved in homodimerisation are underlined. The VEGF sequence depicted includes the 26 amino acid leader sequence (removal of which gives rise to mature VEGF<sub>165</sub>) giving a total length of 191 amino acids.

Homology of SOM175 to VEGF<sub>165</sub> is 27% (33%) at the protein level, however within this are blocks of 100% homology. In particular, many structural residues are conserved including those thought to be involved in homodimerisation of VEGF (by comparison with PDGF).  
ie. Cysteine-47  
Proline-70, Cysteine-72, Valine-74  
Arginine-77, Cysteine-78, Glycine-80, Cysteines-81 & 82  
Cysteine-89, Proline-91  
Cysteines 122 & 124

Fig.6(iii)

APPROVED	O.G. FIG.
BY	CLASS SURCLASS
DRAFTSMAN	W03 027007

08/765588  
PCT/AU96/00094

32/52

SPLICE VARIANTS OF SOM175




Fig. 7

APPROVED	O.G. FIG.
BY	CLASS 62706 SUBCLASS
DRAFTSMAN	

08/765588  
PCT/AU96/00094

33/52

GENOMIC STRUCTURE OF HUMAN SOM175




Fig. 8A

APPROVED BY	O. G. FIG. CLASS	SUBCLASS
DRAFTSMAN		

08/765588  
PCT/AU96/00094

34/52

5'UTR . . .	<b>ATGAGG</b>	*Exon 1 (60bp)	GGCCAG gtacgtgagg
tctccacag	GCCCCCT	Exon 2 (43bp)	GGAAAG aataacttaca
tctgctccca	TGGTGT	Exon 3 (187bp)	ATGCAG gtccgagatg
ctgaatacag	ATCCTC	Exon 4 (73bp)	ATGCAG gtgtcaggca
actttcaag	ACCTAA	Exon 5 (34bp)	AGACAG gtgagtttt
ctcctccgta	GGCTGC	Exon 6 (101bp)	CTCCAG ccccaaggccc
cccactccag	CCCCAG	Exon 7 (109bp)	ACCCAG acacctgttag
ccctgctcag	GTGCCG	*Exon 8 (22bp)	AGGTGA . . . 3' UTR

Fig. 8B

APPROVED	O.G. FIG.
BY	CLASS 16/0001 CLASS
DRAFTSMAN	

08/765588  
PCT/AU96/00094

35/52

36/52	37/52
<i>Fig. 9(i)</i>	<i>Fig. 9(ii)</i>
38/52	39/52
<i>Fig. 9(iii)</i>	<i>Fig. 9(iv)</i>

APPROVED BY	O.G. FIG.
DRAFTSMAN	CLASS SUBCLASS

08/765588  
PCT/AU96/00094

36/52

-163 gcacgagctcaggccgtcgctgcggcgctg  
 -103 gggggccgcggaggagccgccccctgcgcc  
 -43 ggcggctctggctgaccacccacacccg  
  
 16 CGTCGCCTGCTGCTTGCAC TGCTGCAG  
     R R L L L V A L L Q  
     ↓  
 76 TTTGATGGCCCCAGTCACCAGAAGAAAGTG  
     F D G P S H Q K K V  
  
 136 ACATGCCAGCCCAGGGAGGTGGTGGTGCCT  
     T C Q P R E V V V P  
  
 196 AAACAACTAGTGCCAGCTGTGTGACTGTG  
     K Q L V P S C V T V  
  
 256 GGCCTGGAATGTGTGCCACTGGGCAACAC  
     G L E C V P T G Q H  
  
 316 TACCCGAGCAGTCAGCTGGGGAGATGTCC  
     Y P S S Q L G E M S  
  
 376 CCTAAAAAAAAGGAGAGTGCTGTGAGGCCA  
     P K K K E S A V R P  
  
 436 CAGCCCCGCTCTGTTCCGGGCTGGACTCT  
     Q P R S V P G W D S

Fig.9(i)

APPROVED BY	O.G. FIG. 100-20057082
DRAFTSMAN	CLASS SUBCLASS

08/765588  
PCT/AU96/00094

37/52

cgttgcgcgtgcctgcgcggcagggtcgaaaa  
ccgcggccgggtccccgggtccgcgcattgg  
ccgggctaggggcccgATGAGCCCCCTGCTG

M S P L L -17

↓  
CTGGCTCGCACCCAGGCCCCCTGTGTCCCAG

L A R T Q A P V S Q 4

GTGCCATGGATAGACGTTATGCACGTGCC

V P W I D V Y A R A 24

CTGAGCATGGAACTCATGGGCAATGTGGTC

L S M E L M G N V V 44

CAGCGCTGTGGTGGCTGCTGCCCTGACGAT

Q R C G G C C P D D 64

↓  
CAAGTCCGAATGCAGATCCTCATGATCCAG

Q V R M Q I L M I Q 84

↓  
CTGGGAGAACACAGCCAATGTGAATGCAGA

L G E H S Q C E C R 104

↓  
GACAGGGTTGCCATACCCACCAACCGTCCC

D R V A I P H H R P 124

ACCCCGGGAGCACCCCTCCCCAGCTGACATC

T P G A P S P A D I 144

Fig.9(ii)

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	

081765588  
PCTPAU96/00094

38/52

Fig.9(iii)

APPROVED BY	O.G. FIG.
DRAFTSMAN	CLASS SUBCLASS

08/765588  
TCY/AU96/00094

39/52


GCCCGCCTTGCACCCAGCGCCGCCAACGCC										
A	R	L	A	P	S	A	A	N	A	164
C	P	P	C	T	Q	R	R	Q	R	130
GACGCCGCCGCTTCCTCCATTGCCAACGGGC										
D	A	A	A	S	S	I	A	K	G	184
R	R	R	R	F	L	H	C	Q	G	150
↓ GGTGCCGGAAGCCGCGAAAGTGA <u>caagctg</u>										
R	C	R	K	P	R	K	*			186
										167
tatggccctgcttacacagggagaagagagtgg										
gtcactgccccaggacacctggacctttaga										
gctgccatctaacaattgtcaaggaacctc										
tcacttaaccaccctggtcaagtgagcatc										
aaccccaaacttctaccaataacggattt										
acacactcacact <u>gtaaaaagagatgga</u>										
aaaaaaaaaaaaaa										

Fig.9(iv)

APPROVED BY	O.G. FIG. CLASS/ SUBCLASS
DRAFTSMAN	

08/765588  
PCPAU96/00094

40/52



PCPAU96/00094

41/52

A

hVRF167	-21	MSPLLRRLLL AALLQLAPAQAP
mVRF167	-21	MSPLLRRLLL VALLQLARTQAP
		:
hVRF167	30	EVVVPLTVELMGTVAKQLVPSC
		:
mVRF167	30	EVVVPLSMELMGNVVKQLVPSC
		:
hVRF167	80	ILMIRYPSSQLGEMSLEEHHSQC
		:
mVRF167	80	ILMIQYPSSQLGEMSLGEHSQC
		:
hVRF167	130	RPDPRTCRCRCRRRSFLRCQGR
		:
mVRF167	130	RPDPRTCRCRCRRRRFLHCQGR
		:

B

hVRF186	116	RAATPHHRPQPRSVPGWDSAPG
mVRF186	116	RVAIPHHRPQPRSVPGWDSAPG
hVRF186	166	TPGPAAAAADAAAASSVAKGGA*
mVRF186	166	TPGPAAVDAASSIAKGGA*

Fig. 10(i)

42/52

VSQPDAPGHQRKVVSVIDVYTRATCQPR 29  
||| | : | : ||| : ||| ||| ||| ||| ||| |||  
VSQFDGPGSHQKKVVPWIDVYARATCOPR 29

ECRPKKKDSAVKPDSPRPLCPRCTQHHQ 129  
|||||:||||:||||| ||| ||| :|||:  
ECRPKKKESAVRPDSPRILCPPCTQRRO 129

GLELNPDTCRCKLRR\* 167  
|||||: :  
GLELNPDTCRCKPRK\* 167

APSPADITHPTPAPGPSAHAAPSTTSAL 165  
||| ||| ||| ||| ||| : ||| |||  
APSPADIIHPTPAPGSSARLAPSAAANL 165

186


186

Fig. 10(ii)

APPROVED BY	O.G. FIG. CLASS / SUBCLASS
DRAFTSMAN	

08/765588  
PCT/AU96/00094

43/52



APPROVED	Q.G. FIG.	
BY		
DRAFTSMAN	CLASS	SUBCLASS

08/765588  
PCT/AU96/00094

44/52

mVRF167	-21	MSPLLRLRLLVALLQL..	
		::   :	
mVEGF188	-26	MNFLLSWVHWTLALLLYLHH	
mVRF167	25	TCQPREVVVPPLSMELMGNVV	
		:   :   : :: :	
mVEGF188	24	YCRPIETLVDIFQEYPDEIE	
mVRF167	75	QVRMQILMIQYPSSQ.LGEM	
		:      :      :	
mVEGF188	74	NITMQIMRIKPHQSQHIGEM	
mVRF167	119	.....ILCPPC	
		:	
mVEGF188	124	QKRKRKKSRFKSWSVHCEPC	
mVRF167	152	GLENPDTCRCKPRK	
		:	
mVEGF188	173	QLELNERTCRCDKPRR	

Fig.11(i)

APPROVED BY DRAFTSMAN	O.G. FIG. CLASS / SUBCLASS
-----------------------------	-------------------------------

081765588  
PCT/AU96/00094

45/52

Fig. 11(ii)

APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	GW562707

08/765588  
PCT/AU96/00094

46/52





Fig.12

APPROVED	W.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

08/765588  
PCT/AU96/00094

47/52



*Fig. 13*

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN	WO 96/27007	

08/765588

PCT/AU96/00094

49/52




Fig. 15

APPROVED	O.G. FIG.
BY	CLASS 6280 CLASS
DRAFTSMAN	

081765588  
199600094

50/52




Fig. 16

51/52




Fig.17

APPROVED	O.G. FIG.
BY	CLASS
DRAFTSMAN	WO 96/27007

08/765588  
PCT/AU96/00094

52/52

MOUSE ASTROGLIAL CELLS




Fig.18

MOUSE OLIGODENDROGLIAL CELLS




Fig.19

MOUSE FOREBRAIN NEURONS




Fig.20

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**

(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**"A NOVEL GROWTH FACTOR AND A GENETIC SEQUENCE ENCODING SAME"**

the specification of which (check only one item below):

 is attached hereto was filed as United States applicationSerial No. 08/765,588on 17 December 1996

and was amended

on \_\_\_\_\_ (if applicable)

 was filed as PCT international applicationNumber PCT/AU96/00094on 22 February 1996

and was amended under PCT Article 19

on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a)

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:**

COUNTRY (If PCT indicate PCT.)	APPLICATION NUMBER	DATE OF FILING (day month year)	PRIORITY CLAIMED UNDER 35 USC 119
Australia	PN 1457/95	2 March 1995	<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
Australia	PN 6647/95	20 November 1995	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Australia	PN 7274/95	22 December 1995	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

204	FULL NAME OF INVENTOR <i>2/60</i>	FAMILY NAME <b>NORDENSKJOLD</b>	FIRST GIVEN NAME <b>Magnus</b>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY <b>Stockholm</b>	STATE OR FOREIGN COUNTRY <b>Sweden</b>	COUNTRY OF CITIZENSHIP <b>Sweden</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>Koltrastvagen 19</b>	CITY <b>16137 Stockholm</b>	STATE & ZIP CODE/COUNTRY <b>Sweden</b>
205	FULL NAME OF INVENTOR <i>200</i>	FAMILY NAME <b>LARSSON</b>	FIRST GIVEN NAME <b>Catharina</b>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY <b>Stockholm</b>	STATE OR FOREIGN COUNTRY <b>Sweden</b>	COUNTRY OF CITIZENSHIP <b>Sweden</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>Dannemoragatan 10m str</b>	CITY <b>11344 Stockholm</b>	STATE & ZIP CODE/COUNTRY <b>Sweden</b>
206	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
207	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
208	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
209	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 204 <i>Magnus Nordenkjold</i>	SIGNATURE OF INVENTOR 205 <i>Catharina Larsson</i>	SIGNATURE OF INVENTOR 206
DATE <i>9/7/206</i>	DATE <i>9/7/206</i>	DATE
SIGNATURE OF INVENTOR 207	SIGNATURE OF INVENTOR 208	SIGNATURE OF INVENTOR 209
DATE	DATE	DATE

**Combined Declaration For Patent Application and Power of Attorney (Continued)**  
(Includes Reference to PCT International Applications)

ATTORNEY DOCKET NUMBER

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120**

U.S. APPLICATIONS		STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
PCT APPLICATIONS DESIGNATING THE U.S.				
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL NUMBERS ASSIGNED / 3rd y		

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. Stephen D. Murphy, Reg. No. 22,002; Leopold Presser, Reg. No. 19,827; William C. Roch, Reg. No. 24,972; Kenneth L. King, Reg. No. 24,223; Frank S. DiGilio, Reg. No. 31,346; Paul J. Esatto, Jr., Reg. No. 30,749; John S. Sensny, Reg. No. 28,757; Mark J. Cohen, Reg. No. 32,211; Richard L. Catania, Reg. No. 32,608 and Donald T. Black, Reg. No. 27,993.

Send Correspondence to:			Direct Telephone Calls to (Name and telephone number)
<u>Scully, Scott, Murphy &amp; Presser</u> <u>400 Garden City Plaza</u> <u>Garden City, NY 11530</u>			<b>Leopold Presser</b> <b>(516) 742-4343</b>
201	FULL NAME OF INVENTOR <u>201</u>	FAMILY NAME <u>HAYWARD</u>	FIRST GIVEN NAME <u>Nicholas</u>
	RESIDENCE & CITIZENSHIP	CITY <u>Paddington</u>	STATE OR FOREIGN COUNTRY <u>Aux</u> <u>Queensland, Australia</u>
202	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>13 Prince Street</u>	CITY <u>Paddington, Queensland</u>
	FULL NAME OF INVENTOR <u>202</u>	FAMILY NAME <u>WEBER</u>	FIRST GIVEN NAME <u>Gunther</u>
203	RESIDENCE & CITIZENSHIP	CITY <u>Stockholm</u>	STATE OR FOREIGN COUNTRY <u>Sweden</u> <u>SEX</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Ytterenborgsgatan 9nb</u>	CITY <u>11243 Stockholm</u>
204	FULL NAME OF INVENTOR <u>204</u>	FAMILY NAME <u>GRIMMOND</u>	FIRST GIVEN NAME <u>Sean</u>
	RESIDENCE & CITIZENSHIP	CITY <u>Taringa</u>	STATE OR FOREIGN COUNTRY <u>Australia</u> <u>Aux</u> <u>Queensland, Australia</u>
POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>210 Swann Road</u>	CITY <u>Taringa, Queensland</u>	STATE & ZIP CODE COUNTRY <u>4068, Australia</u>


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 203
<u>N. Hayward</u>	<u>Leopold Presser</u>	<u>John S. Sensny</u>
DATE <u>3/3/97</u>	DATE <u>6 February 1997</u>	DATE <u>11th MARCH, 1997</u>

[ ] Signature for fourth and subsequent joint inventors.  
Number of names added

# United States Patent & Trademark Office

## Office of Initial Patent Examination -- Scanning Division



### Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
  - All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".  
Pages \_\_\_\_\_ do not meet these requirements.
  - Papers are not flexible, strong, smooth, non-shiny, durable, and white.
  - Papers are not typewritten or mechanically printed in permanent ink on one side.
  - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
  - Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
  - The drawings or copy of drawings are not suitable for electronic reproduction.
  - All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
  - Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. *Drawing* Page(s) 48 Fig. 14 are not of sufficient clarity, contrast and quality for electronic reproduction.
4. Page(s) \_\_\_\_\_ are missing.
5. OTHER: \_\_\_\_\_